Universe Pharmaceuticals (NASDAQ: UPC) posts $9,036,190 revenue and $1,554,813 net loss

Rhea-AI Filing Summary

Universe Pharmaceuticals INC generated $9,036,190 net revenue for the six months ended March 31, 2026, slightly below $9,152,915 a year earlier. Gross profit rose to $3,342,511, and the net loss narrowed to $1,554,813 from $3,284,755, aided by lower operating expenses and a foreign currency translation gain of $1,070,366.

Cash was $27,559,730 versus $33,592,025 at September 30, 2025, after a $4,298,208 operating cash outflow and $1,812,650 investing outflow, partly offset by stable bank borrowings. The balance sheet shows $71,465,699 in assets, including sizable prepayments for construction and property and a bond investment of $1,490,203. The company faces future capital spending on its new manufacturing facility of $13,888,084, with $3,624,239 expected within 12 months. A dual-class share structure is now in place with 563,338 Class A shares outstanding, and subsequent events include a 2026 equity incentive plan, share awards to the CEO, and an agreed all‑stock acquisition of Best Praise International Limited for $10,751,000 via issuance of 4,376,552 Class A shares.

Positive

• None.

Negative

• Operating cash outflow of $4,298,208 in the half-year, compared with a prior inflow, combined with $13,888,084 in committed construction spending, places greater funding demands on the business.

Filing Explained

Class B voting power remains unused, while 18,750,000 warrants and a share-funded acquisition leave future ownership changes conditional on exercise or closing.

This Form 6-K is an interim report in which the company furnishes unaudited results for the six months ended March 31, 2026 and reports corporate developments.

The dual-class structure authorizes Class A and Class B ordinary shares, but only 563,338 Class A shares were issued and outstanding at March 31, 2026; each Class B share has 100 times the voting rights of a Class A share and is convertible into one Class A share.

The company also reports 18,750,000 common warrants outstanding, each exercisable for one ordinary share through December 2029; none had been exercised as of the reporting date, so they represent potential rather than current share issuance.

The filing records $5,223,594 as a deposit for an acquisition and describes the Best Praise transaction as consideration payable in 4,376,552 Class A shares subject to the SPA's terms; if issued, those additional shares would reduce existing holders' percentage ownership absent offsetting changes.

As of the report date, approximately 38.0% of the $14,956,055 net accounts receivable balance at March 31, 2026 had subsequently been collected.

Key Figures

Net revenue: $9,036,190 Net loss: $1,554,813 Cash balance: $27,559,730 +5 more

8 metrics

Net revenue $9,036,190 For the six months ended March 31, 2026

Net loss $1,554,813 For the six months ended March 31, 2026, compared with $3,284,755 in 2025

Cash balance $27,559,730 Cash as of March 31, 2026

Operating cash flow ($4,298,208) Net cash used in operating activities for the six months ended March 31, 2026

Total assets $71,465,699 Consolidated assets as of March 31, 2026

Future CIP capital expenditure $13,888,084 Estimated future spending on construction-in-progress project after March 31, 2026

Deposit for acquisition company $5,223,594 Recorded in other receivable as of March 31, 2026

Best Praise acquisition price $10,751,000 Consideration payable entirely in 4,376,552 Class A shares under June 17, 2026 SPA

Key Terms

traditional Chinese medicines derivatives, Construction-in-progress, dual-class share structure, Capital Reorganization, +1 more

5 terms

traditional Chinese medicines derivatives medical

"development, manufacturing and sale of traditional Chinese medicines derivatives (“TCMD”) products targeted to the elderly"

Construction-in-progress financial

"Construction-in-progress (“CIP”) represents property and buildings under construction"

dual-class share structure financial

"On February 13, 2026, the dual-class share structure became effective on the Nasdaq Capital Market"

A dual-class share structure is when a company issues two (or more) types of stock that give different voting power: one class typicaly gives founders or insiders more votes per share while the other class, sold to public investors, has little or no voting rights. For investors this matters because it concentrates control in a small group—like a family owning a house with most of the keys—so minority shareholders may have less influence over strategy, governance and risk, which can affect long-term value and accountability.

Capital Reorganization financial

"steps (a) to (e) (inclusive) above shall be collectively referred to as the “Capital Reorganization”"

current expected credit losses (CECL) financial

"replaced the incurred-loss impairment model with a forward-looking current expected credit losses (CECL) model"

Current Expected Credit Losses (CECL) is an accounting standard that requires lenders and companies with loans or receivables to estimate and record the lifetime expected losses up front, rather than waiting until a loss is probable. Investors care because CECL changes reported profits and the amount of reserves a firm must hold — like a household setting aside a larger rainy‑day fund based on forecasted storms — which affects capital, dividend capacity and the perceived financial strength of a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/29/2026 - 04:06 PM Accepted by SEC EDGAR 07/29/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What were Universe Pharmaceuticals (UPC) revenue and net loss for the six months ended March 31, 2026?

Universe Pharmaceuticals reported $9,036,190 net revenue and a net loss of $1,554,813 for the six months ended March 31, 2026. A year earlier, revenue was $9,152,915 with a net loss of $3,284,755, indicating a smaller loss despite similar sales.

How did UPC’s product mix between self-manufactured TCMD and third-party products change in 2026?

Self-manufactured TCMD products contributed 64.8% of revenue in the 2026 half-year, down from 76.2% in 2025. Third-party products rose to 35.2% from 23.8%, reflecting a greater reliance on distributed items despite overall revenue being broadly stable.

What is Universe Pharmaceuticals’ liquidity position and debt as of March 31, 2026?

As of March 31, 2026, UPC held $27,559,730 in cash and $1,490,203 in short-term investments, against total liabilities of $15,820,636. Short-term bank loans were $7,378,950 and long-term bank loans $2,174,543, providing some balance sheet capacity but after an operating cash outflow.

What major capital commitments does UPC have for its construction-in-progress project?

UPC expects future capital expenditures of $13,888,084 on its construction-in-progress manufacturing facility, with about $3,624,239 required within the next 12 months. It had already prepaid roughly $10.0 million to the contractor for land improvement, foundations and factory construction by March 31, 2026.

What significant subsequent events after March 31, 2026 did Universe Pharmaceuticals disclose?

After March 31, 2026, UPC adopted a 2026 Equity Incentive Plan for up to 84,500 shares and granted 71,890 Class A and 12,610 Class B shares to its CEO. It also agreed to acquire Best Praise International Limited for $10,751,000, payable in 4,376,552 new Class A shares.

How concentrated are Universe Pharmaceuticals’ revenues by product and geography?

Sales of Guben Yanling Pill accounted for 40.0% of total revenue in both 2026 and 2025 half-years, indicating major product concentration. All revenues and substantially all assets are in the PRC, with products sold across 30 provinces, creating geographic and regulatory concentration risk in China.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission file number: 001-40231

Universe Pharmaceuticals INC
 

265 Jingjiu Avenue
Jinggangshan Economic and Technological Development Zone
Ji’an, Jiangxi, China 343100
+86-0796-8403309
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Explanatory Note

Universe Pharmaceuticals INC (the “Company”) is filing this current report on Form 6-K to report its financial results as of and for the six months ended March 31, 2026 and to discuss its recent corporate developments.

Attached as exhibits to this current report on Form 6-K are:

	(1)	the unaudited condensed interim consolidated financial statements and related notes as Exhibit 99.1;
	(2)	Management’s Discussion and Analysis of Financial Condition and Results of Operations as Exhibit 99.2;
	(3)	Interactive Data Files as Exhibit 101, in accordance with Rule 405 of Regulation S-T.

1

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements in this current report with respect to the Company’s current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of the Company. Forward-looking statements include, but are not limited to, those statements using words such as “believe,” “expect,” “plans,” “strategy,” “prospects,” “forecast,” “estimate,” “project,” “anticipate,” “aim,” “intend,” “seek,” “may,” “might,” “could” or “should,” and words of similar meaning in connection with a discussion of future operations, financial performance, events or conditions. From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management’s assumptions, judgments and beliefs in light of the information currently available to it. The Company cautions investors that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements, including but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission. Therefore, investors should not place undue reliance on such forward-looking statements. Actual results may differ significantly from those set forth in the forward-looking statements.

All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Unaudited Consolidated Financial Statements and Related Notes as of March 31, 2026 and for the Six Months Ended March 31, 2026 and 2025
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations
101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

3

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Universe Pharmaceuticals INC.
Date: July 29, 2026	By:	/s/ Gang Lai
		Gang Lai
		Chief Executive Officer

4

Exhibit 99.1

UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In U.S. dollars, except share and per share data) 

		As of
		March 31, 2026				September 30, 2025
		(Unaudited)				(Audited)
ASSETS
CURRENT ASSETS
Cash		$	27,559,730			$	33,592,025
Short-term investments			1,490,203				-
Accounts receivable, net			14,956,055				13,008,117
Inventories, net			1,979,795				2,193,179
Advance to suppliers			2,001,693				2,489,737
Other receivable			7,180,731				2,280,680
Prepaid expenses and other current assets			41,216				39,937
TOTAL CURRENT ASSETS			55,209,423				53,603,675
Property, plant and equipment, net			3,787,567				3,583,553
Prepayments made to a related party for purchase of property			2,319,513				2,247,507
Prepayments for construction in progress			9,114,598				8,869,574
Intangible assets, net			309,750				296,785
Investment in equity securities			724,848				702,346
TOTAL NON-CURRENT ASSETS			16,256,276				15,699,765
TOTAL ASSETS		$	71,465,699			$	69,303,440
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES
Short-term bank loans		$	7,378,950			$	7,149,881
Current portion of long-term bank loans			-				2,107,038
Accounts payable			3,754,356				1,669,785
Contract liabilities			42,012				40,708
Taxes payable			655,647				640,780
Due to related parties			157,294				446,545
Other payable			1,405,962				856,572
Accrued expenses and other current liabilities			251,872				262,621
TOTAL CURRENT LIABILITIES			13,646,093				13,173,930
Long-term bank loans			2,174,543				-
TOTAL LIABILITIES			15,820,636				13,173,930
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY
Class A ordinary shares, $0.00001 par value, 1,800,000,000 shares authorized, 563,338 shares issued and outstanding as of March 31, 2026; Ordinary shares, $11.25 par value, 2,000,000,000 shares authorized, 563,338 shares issued and outstanding as of September 30, 2025 *			6				6,337,553
Class B ordinary shares, $0.00001 par value, 200,000,000 shares authorized, none issued and outstanding as of March 31, 2026; Class B ordinary shares, $0.00001 par value, none authorized, issued and outstanding as of September 30, 2025							-
Additional paid in capital			69,347,114				63,009,567
Statutory reserve			2,439,535				2,439,535
Accumulated deficit			(15,398,436	)			(13,843,623	)
Accumulated other comprehensive loss			(743,156	)			(1,813,522	)
TOTAL SHAREHOLDERS’ EQUITY			55,645,063				56,129,510
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$	71,465,699			$	69,303,440

* The dual-class share structure became effective on February 13, 2026.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-1

UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(UNAUDITED)

(In U.S. dollars, except share and per share data) 

		For the Six Months Ended March 31,
		2026				2025
Revenue		$	9,036,190			$	9,152,915
Cost of revenue and related tax			5,693,679				5,988,385
Gross profit			3,342,511				3,164,530
Operating expenses
Selling expenses			3,285,367				2,276,728
General and administrative expenses			1,463,798				3,117,727
Research and development expenses			93,478				96,836
Total operating expenses			4,842,643				5,491,291
Loss from operations			(1,500,132	)			(2,326,761	)
Other income (expenses)
Interest expense, net			(126,157	)			(128,745	)
Other income (expense), net			71,476				(829,249	)
Total other expense, net			(54,681	)			(957,994	)
Loss before income tax expense			(1,554,813	)			(3,284,755	)
Income tax expense			-				-
Net loss			(1,554,813	)			(3,284,755	)
Other comprehensive loss
Foreign currency translation adjustment			1,070,366				(2,033,233	)
Comprehensive loss		$	(484,447	)		$	(5,317,988	)
Net loss per share - Basic and diluted		$	(2.76	)		$	(9.44	)
Weighted average number of shares outstanding used in calculating basic and diluted loss per share		$	563,338			$	347,814

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

FOR THE SIX MONTHS ENDED MARCH 31, 2026 AND 2025

(UNAUDITED)

(In U.S. dollars, except share and per share data) 

																						Accumulated
										Additional												Other
		Ordinary Share								Paid in				Statutory				Accumulated				Comprehensive
		Shares				Amount				Capital				Reserve				Deficit				Loss				Total
Balance as of September 30, 2024			42,880			$	482,400			$	53,864,720			$	2,439,535			$	(10,171,568	)		$	(1,112,146	)		$	45,502,941
Issuance of ordinary shares			468,750				5,273,438				9,726,562				-				-				-				15,000,000
Reverse share-split adjustment			51,708				581,715				(581,715	)			-				-				-				-
Net loss			-				-				-				-				(3,284,755	)			-				(3,284,755	)
Foreign currency translation adjustment			-				-				-				-				-				(2,033,233	)			(2,033,233	)
Balance as of March 31, 2025			563,338			$	6,337,553			$	63,009,567			$	2,439,535			$	(13,456,323	)		$	(3,145,379	)		$	55,184,953

		Ordinary Share								Additional Paid in				Statutory				Accumulated				Accumulated Other Comprehensive
		Shares *				Amount				Capital				Reserve				Deficit				Loss				Total
Balance as of September 30, 2025			563,338			$	6,337,553			$	63,009,567			$	2,439,535			$	(13,843,623	)		$	(1,813,522	)		$	56,129,510
The effect of adoption dual-class chare structure			-				(6,337,547	)			6,337,547				-				-				-				-
Net loss			-				-				-				-				(1,554,813	)			-				(1,554,813	)
Foreign currency translation adjustment			-				-				-				-				-				1,070,366				1,070,366
Balance as of March 31, 2026			563,338			$	6			$	69,347,114			$	2,439,535			$	(15,398,436	)		$	(743,156	)		$	55,645,063

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-3

UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(In U.S. dollars, except share and per share data) 

		For the Six Months Ended March 31,
		2026				2025
Cash flows from operating activities:
Net loss		$	(1,554,813	)		$	(3,284,755	)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			231,217				269,639
Changes in operating assets and liabilities:
Accounts receivable			(1,507,555	)			2,318,451
Inventories			279,272				(1,892,889	)
Advance to suppliers, net			559,050				(1,057,671	)
Other receivable			(4,794,563	)			3,555,781
Prepaid expenses and other current assets			-				787,964
Accounts payable			1,999,735				2,657,313
Taxes payable			(5,575	)			(871,160	)
Other payable			513,894				-
Accrued expenses and other current liabilities			(18,870	)			78,521
Net cash (used in) provided by operating activities			(4,298,208	)			2,561,194
Cash flows from investing activities:
Purchases of property, plant and equipment			(311,028	)			(84,333	)
Prepayments for construction in progress			-				(12,447	)
Purchase of intangible asset			(11,419	)			(35,957	)
Purchase of short-term investments			(1,490,203	)			-
Net cash used in investing activities			(1,812,650	)			(132,737	)
Cash flows from financing activities:
Net proceeds from issuance of ordinary shares			-				15,000,000
Proceeds from bank loans			3,568,319				691,486
Repayment of bank loans			(3,568,319	)			(691,486	)
Proceeds from related party borrowings			-				1,398,355
Repayment of related party borrowings			(149,072	)			-
Net cash (used in) provided by financing activities			(149,072	)			16,398,355
Effect of changes of foreign exchange rates on cash			227,635				(1,051,654	)
Net (decrease) increase in cash			(6,032,295	)			17,775,158
Cash, beginning of period			33,592,025				29,497,693
Cash, end of period		$	27,559,730			$	47,272,851
Supplemental disclosure of cash flow information
Cash paid for interest		$	159,395			$	150,009
Cash paid for income tax		$	-			$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-4

UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES

 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION

Universe Pharmaceuticals INC (“Universe INC” or the “Company”) was incorporated under the laws of the Cayman Islands on December 11, 2019 as an exempted company with limited liability.

Universe INC owns 100% of the equity interests in Universe Pharmaceuticals (International) Group (“Universe HK”), an entity incorporated on May 21, 2014 in accordance with the laws and regulations in Hong Kong.

Jiangxi Universe Pharmaceuticals Technology Co., Ltd. (“Universe Technology”) was formed on April 8, 2019, as a wholly foreign-owned enterprise (“WFOE”) in the People’s Republic of China (the “PRC” or “China”).

Universe INC, Universe HK and Universe Technology are currently not engaging in any active business operations and are merely acting as holding companies.

Jiangxi Universe Pharmaceuticals Co., Ltd. (“Jiangxi Universe”) was incorporated on March 2, 1998 in accordance with PRC laws and is engaged in the research and development and manufacturing of modernized traditional Chinese medicines. Jiangxi Universe owns 100% of the equity interests of Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (“Universe Trade”), which was incorporated on March 10, 2010 for the purposes of handling the sales and distribution of the pharmaceutical products manufactured by Jiangxi Universe.

Reorganization

A reorganization of the Company’s legal structure (the “Reorganization”) was completed on December 11, 2019. The Reorganization involved the incorporation of Universe INC and Universe Technology, and the transfer of 100% of the equity interests of Jiangxi Universe to Universe Technology. Consequently, Universe INC, through its subsidiary Universe HK, directly controls Universe Technology and Jiangxi Universe, and became the ultimate holding company of all other entities mentioned above.

The Reorganization has been accounted for as a recapitalization among entities under common control, since the same controlling shareholders controlled all these entities before and after the Reorganization. Results of operations for the periods presented eliminate the effects of intra-entity transactions.

On March 25, 2021, the Company closed its initial public offering (the “IPO”) of 5,000,000 ordinary shares, par value $0.003125 per share at a public offering price of $5.00 per share. On March 29, 2021, the underwriter exercised in full its over-allotment option to purchase an additional 750,000 ordinary shares. The closing for the sale of the over-allotment shares took place on September 30, 2021. Gross proceeds from the IPO totaled $28.75 million. Net proceeds of the IPO, including over-allotment shares, were approximately $25.6 million. In connection with the IPO, the Company’s ordinary shares began trading on the Nasdaq Global Market under the symbol “UPC” on March 23, 2021.

On May 12, 2021, through the Company’s PRC subsidiary, Jiangxi Universe, the Company established an indirect wholly controlled subsidiary, Guangzhou Universe Hanhe Medical Research Co., Ltd. (“Universe Hanhe”) in Guangzhou City, China, for the business purpose of conducting research and development of new pharmaceutical products in order to diversify the Company’s product offerings. As of September 30, 2025 and as of the date of this report, Universe Hanhe has no active business operations.

On July 3, 2023, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:

(a) with immediate effect, to increase the Company’s authorized share capital from US$312,500 divided into 90,000,000 ordinary shares of par value US$0.003125 each and 10,000,000 preferred shares of par value US$0.003125 each, to US$3,125,000 divided into 900,000,000 ordinary shares of par value US$0.003125 each and 100,000,000 preferred shares of par value US$0.003125 each;

(b) that, conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of the Company may determine, the authorized, issued and outstanding shares of the Company be consolidated by consolidating each 10 shares of the Company, or such lesser whole share amount as the board of directors may determine in its sole discretion, such amount not to be less than 2, into 1 share of the Company, with such consolidated shares having the same rights and being subject to the same restrictions (save as to nominal value) as the then existing shares of par value US$0.003125 each in the capital of the Company (the “2023 Share Consolidation”); and

F-5

(c) that, upon the effectiveness of the 2023 Share Consolidation, the Company adopt amended and restated articles of association, in substantially the form set out in Annex B in the proxy statement dated May 24, 2023, in substitution for and to the exclusion of, the memorandum of association of the Company in effect immediately prior to effectiveness of the Share Consolidation.

The board of directors of the Company resolved to effect the 2023 Share Consolidation on July 27, 2023 with the authorized, issued and outstanding shares to be consolidated on a six (6) for one (1) ratio, which had the effect of reducing the number of: (a) authorized ordinary shares from 900,000,000 ordinary shares with a par value of US$0.003125 per share to 150,000,000 ordinary shares with a par value of US$0.01875 per share; (b) issued and outstanding ordinary shares from 21,750,000 ordinary shares with a par value of US$0.003125 per share to 3,625,000 ordinary shares with a par value of US$0.01875 per share; and (c) authorized preferred shares from 100,000,000 preferred shares with a par value of US$0.003125 per share to 16,666,666.6666 preferred shares with a par value of US$0.01875 per share.

On July 15, 2024, the Company closed its self-underwritten public offering of 20,000,000 ordinary shares, par value $0.01875 per share. The ordinary shares were priced at $1.25 per share. The Company raised a total of $25 million through that offering, before deducting offering-related expenses, and net proceeds of $24.625 million.

On September 27, 2024, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:

(a) with immediate effect, to increase the Company’s authorized share capital from US$3,125,000 divided into 150,000,000 ordinary shares of par value US$0.01875 each and 16,666,666.6666 preferred shares of par value US$0.01875 each, to US$140,625,000 divided into 6,750,000,000 ordinary shares of par value US$0.01875 each and 750,000,000 preferred shares of par value US$0.01875 each (the “Authorized Share Capital Increase”);

(b) that, subject to and immediately following the Authorized Share Capital Increase being effected, the Company adopt an amended and restated memorandum of association in substitution for, and to the exclusion of, the Company’s existing memorandum of association, to reflect the Authorized Share Capital Increase; and

(c) that, conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of the Company may determine, the authorized, issued, and outstanding shares of the Company (collectively, the “Shares”) be consolidated by consolidating each 15 Shares of the Company, or such lesser whole share amount as the Company’s board of directors may determine in its sole discretion, such amount not to be less than 2, into 1 Share of the Company, with such consolidated Shares having the same rights and being subject to the same restrictions (save as to nominal value) as the existing Shares of such class as set out in the Company’s memorandum and articles of association (the “2024 Share Consolidation”).

On November 12, 2024, the Company effected a share consolidation of 15 ordinary shares with par value of US$0.01875 per share each in the Company’s issued and unissued share capital into one (1) ordinary share with par value of US$0.28125. All fractional shares were rounded up to the whole number of shares (the “2024 Share Consolidation”). Immediately following the 2024 Share Consolidation, the authorized share capital of the Company was US$140,625,000 divided into 450,000,000 ordinary shares, par value US$0.28125 per share and 50,000,000 preferred shares, par value US$0.28125 per share.

On March 24, 2025, the Company effected a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company’s issued and unissued share capital into one ordinary share with par value of US$11.25. All fractional shares were rounded up to the whole number of shares (the “2025 Share Consolidation”). Immediately following the 2025 Share Consolidation, the authorized share capital of the Company was US$140,625,000 divided into 11,250,000 ordinary shares, par value US$11.25 per share and 1,250,000 preferred shares, par value US$11.25 per share.

F-6

On September 3, 2025, the Company held an annual general meeting of shareholders at which shareholders, resolved as a special resolution that, subject to and conditional upon, amongst other things: (i) approval from the Grand Court of the Cayman Islands (the “Court”) of the Capital Reduction (as defined below); (ii) registration by the Registrar of Companies of the Cayman Islands of the order of the Court confirming the Capital Reduction and the minute approved by the Court containing the particulars required under the Companies Act (Revised) (the “Act”) in respect of the Capital Reduction and compliance with any conditions the Court may impose; (iii) compliance with the relevant procedures and requirements under the applicable laws of the Cayman Islands to effect the Capital Reduction; and (iv) obtaining of all necessary approvals from the regulatory authorities or otherwise as may be required in respect of the Capital Reduction, with effect from the date on which these conditions are fulfilled:

a) the par value of each issued Ordinary Share of par value US$11.25 each in the share capital of the Company be reduced to par value US$0.00001 each (the “Capital Reduction”) by cancelling the paid-up capital to the extent of US$11.24999 on each of the then issued Ordinary Shares of par value US$11.25 each;

b) the credit arising from the Capital Reduction be transferred to a distributable reserve account of the Company which may be utilized by the Company as the board of directors of the Company may deem fit and as permitted under the Act, the amended and restated memorandum of association adopted by special resolution passed on 1 March 2025 and unanimous written director resolutions passed on 20 February 2025 and made effective on 17 March 2025 (the “Existing Memorandum”), the second amended and restated articles of association of the Company adopted by special resolution passed on 23 September 2022 (the “Existing Articles”), and all relevant applicable laws, including, without limitation, eliminating or setting off any accumulated losses of the Company (if any) from time to time;

c) immediately following the Capital Reduction, pursuant to section 13 of the Act and article 8.1(d) of the Existing Articles, each of the authorized but unissued Ordinary Shares of par value US$11.25 each be sub-divided into 1,125,000 ordinary shares of par value US$0.00001 each (the “Sub-division”);

d) immediately following the Capital Reduction and the Sub-division, the authorized share capital of the Company be altered by the cancellation of: (i) the 1,250,000 unissued Preferred Shares of par value US$11.25 each; and (ii) 12,020,495,313,338 of the unissued ordinary shares of par value US$0.00001 each, such that the authorized share capital is altered:

from US$134,287,453.13338 divided into: (i) 12,022,495,313,338 ordinary shares of par value US$0.00001 each; and (ii) 1,250,000 Preferred Shares of par value US$11.25 each;

to US$20,000 divided into 2,000,000,000 ordinary shares of par value US$0.00001 each

(the “Capital Alteration”);

e) immediately following the Capital Alteration:

a. the authorized and issued share capital of the Company be divided into two separate classes as follows:

i. US$18,000 divided into 1,800,000,000 class A ordinary shares of par value US$0.00001 each (the “Class A Ordinary Shares”); and

ii. US$2,000 divided into 200,000,000 class B ordinary shares of par value US$0.00001 each (the “Class B Ordinary Shares” and, together with the Class A Ordinary Shares, the “New Share Classes”),

it being noted that the terms of, and rights attaching to the New Share Classes will be materially identical to the existing ordinary shares of par value US$0.00001 each in the capital of the Company save that the Class B Ordinary Shares: (i) shall have 100 times the voting rights per share of Class A Ordinary Shares; and (ii) shall be convertible into Class A Ordinary Shares;

b. the issued shares in the Company outstanding following the Capital Alteration be re-designated, as follows:

i. the 559,868 ordinary shares of par value US$0.00001 each held by Cede & Co be re-designated as 559,868 Class A Ordinary Shares;

F-7

ii. the 1 ordinary share of par value US$0.00001 held by Christopher Lin be re-designated as 1 Class A Ordinary Share;

iii. the 1 ordinary share of par value US$0.00001 held by Michael Olson be re-designated as 1 Class A Ordinary Share;

iv. the 1 ordinary share of par value US$0.00001 held by Daniel J Sleiman be re-designated as 1 Class A Ordinary Share; and

v. the 3,467 ordinary shares of par value US$0.00001 each held by Sununion Holding Group Limited be re-designated as 3,467 Class B Ordinary Shares,

(steps (a) to (e) (inclusive) above shall be collectively referred to as the “Capital Reorganization”),

f) any one or more of the directors of the Company be and is/are hereby authorized to do all such acts and things and execute all such documents, which are in connection with and/or ancillary to the Capital Reorganization and any of the foregoing steps and of administrative nature, on behalf of the Company, including under seal where applicable, as they consider necessary, desirable or expedient to give effect to the foregoing arrangements for the Capital Reorganization and (where applicable) to aggregate all fractional Class A Ordinary Shares and/or Class B Ordinary Shares and sell them for the benefit of the Company.”

On February 13, 2026, the dual-class share structure became effective on the Nasdaq Capital Market, and the Company’s authorized share capital was changed to US$20,000 divided into 1,800,000,000 class A ordinary shares of par value US$0.00001 each (the “Class A Ordinary Shares”) and 200,000,000 class B ordinary shares of par value US$0.00001 each.

Details of the subsidiaries of the Company as of March 31, 2026 are set out below:

		Date of		Place of		% of
Name of Entity		Incorporation		Incorporation		Ownership		Principal Activities
Universe INC		December 11, 2019		Cayman Islands		Parent, 100%		Investment holding
Universe HK		May 21, 2014		Hong Kong		100%		Investment holding
Universe Technology		April 18, 2019		PRC		100%		WFOE, Investment holding
Jiangxi Universe		March 2, 1998		PRC		100%		Research and development and manufacturing of modernized traditional Chinese medicines
Universe Trade		March 10, 2010		PRC		100%		Sales of modernized traditional Chinese medicines
Universe Hanhe		May 12, 2021		PRC		100%		Research and development of new pharmaceutical products

The Company, through its wholly-owned subsidiaries, is primarily engaged in the development, manufacturing and sale of traditional Chinese medicines derivatives (“TCMD”) products targeted to the elderly to address their physical conditions in the aging process and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical instruments, traditional Chinese medicine pieces products and dietary supplements (collectively, “third-party products”). All of these TCMD and third-party products are currently sold to customers including pharmaceutical companies, hospitals, clinics and drugstore chains throughout China.

F-8

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and the notes thereto for the year ended September 30, 2025 included in the Form 20-F filed on January 28, 2026. Operating results for the six months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2026. All inter-company balances and transactions are eliminated upon consolidation.

Uses of estimates

In preparing the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information as of the date of the unaudited condensed consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, the impairment assessment of receivables, the realizability of advance to suppliers, inventory valuations, useful lives of property, plant and equipment and intangible assets, impairment assessment of long-lived assets, and realization of deferred tax assets. Changes in accounting estimate are accounted for in the period of change and prospective periods. Actual results could differ from those estimates.

Risks and Uncertainties

The business operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results.

The development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition with respect to its current and future pharmaceutical product candidates from major pharmaceutical companies in China.

The Company’s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company’s operations.

Cash

Cash includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of its bank accounts in the PRC. Cash maintained in banks within the PRC of less than RMB0.5 million (equivalent to $72,485) per bank are covered by “deposit insurance regulation” promulgated by the State Council of the PRC.

F-9

Accounts receivable, net

Accounts receivable are recorded at the gross billing amount less an allowance for any uncollectible accounts due from the customers. Accounts receivable do not bear interest.

Effective October 1, 2022, the Company adopted Accounting Standards Update (“ASU”) No.2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), using the modified retrospective transition method. ASU 2016-13 replaces the existing incurred-loss impairment model with an expected-loss methodology, which will result in more timely recognition of credit losses. Upon adoption, the Company replaced the incurred-loss impairment model with a forward-looking current expected credit losses (CECL) model in place of the incurred-loss methodology for financial instruments measured at amortized cost and receivables resulting from the application of ASC 606, including contract assets.

The Company maintains an allowance for credit losses and records the allowance for credit losses as an offset to accounts receivable. Estimated credit losses charged to the allowance are classified as “General and administrative expenses” in the unaudited condensed consolidated statements of operations and comprehensive loss. The Company assesses collectability by reviewing accounts receivable on an aging schedule basis, as accounts receivable primarily consist of receivables arising from sales of TCMD products and third-party products. In determining the amount of the allowance for credit losses, the Company considers historical collectability based on past due status, the age of the balances, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect the Company’s ability to collect from its customers. Delinquent account balances are written off against the allowance for expected credit losses after management has determined that the likelihood of collection is not probable.

The allowance for uncollectible balances amounted to $18,797 and $18,214 as of March 31, 2026 and September 30, 2025, respectively.

Inventories, net

Inventories are stated at lower of cost or net realizable value. Cost is determined using weighted average method. Inventories primarily consist of raw materials and finished goods. Inventory costs include the purchase price and other expenditures that are directly attributable to bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments, and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future product sales. The Company recorded inventory reserve of $126,671 and $122,739 as of March 31, 2026 and September 30, 2025, respectively.

Advances to suppliers, net

Advances to suppliers represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices of raw materials. These advances are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time to make cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company when the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of March 31, 2026 and September 30, 2025, the Company recorded no allowance for credit loss, as the Company believed that all advances to suppliers were fully realizable.

Fair value of financial instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

● Level 1 —  inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

F-10

● Level 2 —  inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated by observable market data.

● Level 3 —  inputs to the valuation methodology are unobservable.

ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future cash flow amounts discounted at market interest rates to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.

Unless otherwise disclosed, the fair value of the Company’s financial instruments, including cash, short-term investment, accounts receivable, inventories, accounts payable, short-term bank loans, accrued expenses and other current liabilities and due to related parties, approximate the fair value of the respective assets and liabilities as of March 31, 2026 based upon the short-term nature of the assets and liabilities. The Company’s investment in equity securities is accounted for using the measurement alternative in accordance with Accounting Standards Codification (“ASC”) 321, “Investments—Equity Securities” (“ASC 321”), which also approximates its recorded value. The carrying amount of long-term bank loan approximates its fair value as the loan is priced at market interest rate.

Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation of property, plant and equipment is provided using the straight-line method over their expected useful lives, as follows:

Categories		Useful life
Buildings		20 years
Machinery and equipment		5–10 years
Automobiles		3–5 years
Office and electric equipment		3–5 years

Expenditures for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the unaudited condensed consolidated statements of operations and comprehensive loss in other income or expenses.

The Company reviews the carrying value of property, plant and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this assessment, no impairment expenses for property, plant and equipment were recorded in operating expenses for the six months ended March 31, 2026 and 2025.

F-11

Intangible Assets

Intangible assets consist primarily of land use rights, trademarks and software. Under PRC law, all land in the PRC is owned by the government and cannot be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for specified periods of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the straight-line method with the following estimated useful lives:

Categories		Useful life
Land use rights		50 years
Trademark		5 years
Software		3 years

The Company reviews the carrying value of intangible assets for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this assessment, no impairment of land use rights was deemed necessary for the six months ended March 31, 2026 and 2025.  

Construction-in-Progress (“CIP”)

CIP represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct costs attributable to the construction. CIP is not depreciated. Upon completion and when ready for its intended use, CIP is reclassified to the appropriate category within property, plant and equipment.

Impairment of Long-Lived Assets

Long-lived assets with finite lives, primarily property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash flows from the use of the asset and its eventual disposition are below the asset’s carrying value, then the asset is deemed to be impaired and written down to its fair value. The Company recognized an impairment loss of $503,044 and $487,428 for prepayments for CIP as of March 31, 2026 and September 30, 2025, respectively.

Investments in Equity Securities

The Company accounts for its equity investments in accordance with ASC 321. In accordance with ASC 321, equity investments in which the Company has no significant influence (generally less than a 20% ownership interest) with readily determinable fair values are accounted for at fair value based on quoted market prices with the changes in fair value recognized as unrealized gains or losses in earnings. Equity investments without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment.

From March 2009 to September 2017, the Company invested approximately $0.7 million (RMB5 million) in Jiangxi Jian Rural Commercial Bank (“JX RCB Bank”) in exchange for  a 5% ownership interest in the bank. The purpose of entering into these equity investment agreements with JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that this investment in equity securities does not have a readily determinable fair value and, accordingly, elected the measurement alternative noted above.

The Company initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated earnings of the investee as income. As of March 31, 2026 and September 30, 2025, the Company’s investment in JX RCB Bank amounted to $724,848 (RMB5 million) and $702,346 (RMB5 million), respectively, and was reported as long-term investment in equity investee on the unaudited condensed consolidated balance sheets. Investment income was nil for the six months ended March 31, 2026 and 2025.

F-12

The investments in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the investments is less than their carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary. The Company reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited to: (i) the nature of the investment; (ii) the cause and duration of the impairment; (iii) the extent to which fair value is less than cost; (iv) the financial condition and near-term prospects of the investments; and (v) the ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in fair value. There was no impairment of the Company’s investments in equity securities as of March 31, 2026 and September 30, 2025.

Revenue Recognition

To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

Revenue from sales of TCMD products and third-party products is recognized when the products are delivered to customers. Each customer order is distinct and separately identifiable from other customer orders, constituting a single performance obligation to deliver the ordered product in exchange for consideration. The transaction price is fixed at contract inception and is not subject to rebates, returns or other variable consideration. As each customer order includes only one performance obligation and no variable consideration, no allocation of the transaction price is required. The Company recognizes revenue at a point in time when the control of the products sold has been transferred to customers. The transfer of control is considered complete when the products have been accepted and received by customers. The Company offers credit sales to customers with a credit period of 90 days.

Revenue is presented on a gross basis, as the Company acts as the principal in each transaction. This conclusion is based on the following considerations: (i) the Company is primarily responsible for fulfilling the promise to deliver the product to the customer and is the primary contact for customer issues; (ii) the Company bears the inventory risk; and (iii) the Company has pricing discretion and bears market risk.

Disaggregation of Revenues

The Company disaggregates its revenue from contracts with customers by source of products, as the Company believes such disaggregation best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows are affected by economic factors. The following table sets forth the disaggregation of the Company’s revenue for the six months ended March 31, 2026 and 2025, respectively:

		For the Six Months Ended March 31,
		2026				2025
Revenue from sales of self-manufactured TCMD products		$	5,850,980			$	6,978,932
Revenue from sales of third-party products			3,185,210				2,173,983
Total revenue		$	9,036,190			$	9,152,915

Cost of Revenue

Cost of revenue consists primarily of the costs of raw materials, freight charges, direct labor, depreciation of buildings and machinery, warehousing and overhead associated with the manufacturing process.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and benefits paid to administrative personnel, office supplies and utility expenses, depreciation of office equipment, consulting fees, and other miscellaneous administrative expenses.

F-13

Research and Development Expenses

The Company expenses all internal research and development costs as incurred, which primarily comprise employee costs, internal and external costs related to the execution of studies, manufacturing costs, facility costs of the research center, and depreciation and amortization of intangible assets and property, plant and equipment used in research and development activities. For the six months ended March 31, 2026 and 2025, total research and development expenses were approximately $93,478 and $96,836, respectively.

Shipping and Handling Costs

Shipping and handling costs are expensed as incurred. Inbound shipping and handling costs associated with bringing purchased raw materials and third-party products from suppliers to the Company’s warehouse are included in cost of revenue. Outbound shipping and handling costs associated with shipping and delivering the products to customers are included in selling expenses.

Advertising Expenses

Advertising expenses primarily relate to the promotion of the Company’s brand name and products through outdoor billboards, social media platforms such as Weibo and WeChat, and television advertisements. Advertising costs are expensed as incurred or, where deferred, expensed the first time the advertising takes place. Advertising expenses are included in selling expenses in the unaudited condensed consolidated statements of operations and comprehensive loss. Advertising expenses amounted to $1,912,566 and $1,248,783 for the six months ended March 31, 2026 and 2025, respectively.

Segment Reporting

In accordance with ASC 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company utilizes the management approach to identify its reportable operating segments.

The management approach considers the internal organizational structure and reporting mechanisms employed by the Company’s CODM for operational decision-making and performance evaluation. The Company’s chief executive officer has been designated as the CODM, who reviews and evaluates the consolidated results of operations to determine resource allocation and assess the Company’s overall performance.

Based on this assessment, the Company has concluded that it operates as a single reportable operating segment. For management purposes, the Company operates in one business unit based on the products sold, and its sole operating segment is pharmaceutical manufacturing and selling. The CODM monitors the revenue, results of operations, assets and liabilities of its business unit as a whole and regularly reviews its operating results to make decisions about resource allocation. Accordingly, no analysis of segment information other than entity-wide information is presented.

The Company’s long-lived assets are all located in the PRC and substantially all of the monitoring and control activities of its operations are conducted in the PRC. Accordingly, no geographic information is presented.

The significant segment expenses are consistent with those reported in the unaudited condensed consolidated statements of operations and comprehensive loss, including cost of revenue, selling expenses, general and administrative expenses, and research and development expenses. For the significant segment expenses incurred during the six months ended March 31, 2026 and 2025, refer to the unaudited condensed consolidated statements of operations and comprehensive loss.

F-14

Income Taxes

The Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

An uncertain tax position is recognized only if it is “more likely than not” that the tax position would be sustained upon examination by the relevant tax authority. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized upon examination. For tax positions not meeting the “more likely than not” threshold, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest relating to income taxes were incurred during the six months ended March 31, 2026 and 2025. The Company does not believe there were any uncertain tax positions as of March 31, 2026 and September 30, 2025.

The Company’s operating subsidiaries in China are subject to the income tax laws of the PRC. No significant income was generated outside the PRC for the six months ended March 31, 2026 and 2025. As of March 31, 2026 and September 30, 2025, all tax returns of the Company’s PRC subsidiaries remained open for statutory examination by the PRC tax authorities.

Value Added Tax (“VAT”)

Sales revenue represents the invoiced value of goods, net of VAT. The VAT is based on the gross sales price, and VAT rates range up to 13%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company records a VAT payable or receivable, net of payments, in the accompanying unaudited condensed consolidated financial statements.

Earnings per Share

The Company computes earnings per share (“EPS”) in accordance with ASC 260, “Earnings per Share” (“ASC 260”). ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average ordinary shares outstanding for the period. Diluted EPS presents the dilutive effect on a per-share basis of potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. For the six months ended March 31, 2026 and 2025, there were no dilutive shares.

Foreign Currency Translation

The functional currency for Universe INC is the U.S. Dollar (“US$”). Universe HK uses the Hong Kong dollar as its functional currency. However, Universe INC and Universe HK currently serve solely as holding companies and had no active operations as of the date of this report. The Company operates only in the PRC and the Company’s functional currency is the Chinese Yuan (“RMB”). The Company’s unaudited condensed consolidated financial statements have been translated into the reporting currency US$.

Assets and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation adjustments are reported in other comprehensive income. Gains and losses resulting from the translation of foreign currency transactions and balances are reflected in the results of operations.

F-15

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.

The following table sets forth the currency exchange rates used in preparing the unaudited condensed consolidated financial statements in this report:

		March 31, 2026				March 31, 2025				September 30, 2025
Period-end US$: RMB exchange rate			6.8980				7.2567				7.1190
Period-end US$: HK exchange rate			7.8400				7.7799				7.7809
Period average US$: RMB exchange rate			7.0061				7.2308				7.2125
Period average US$: HK exchange rate			7.7954				7.7771				7.7948

Comprehensive Income

Comprehensive income consists of two components, net income and other comprehensive income. The foreign currency translation gain resulting from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income in the unaudited condensed consolidated statements of operations and comprehensive loss.

Statement of Cash Flows

In accordance with ASC 230, “Statement of Cash Flows,” cash flows from the Company’s operations are calculated based on the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.

Employee Defined Contribution Plan

The Company’s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefits, and housing fund are provided to eligible full-time employees. The relevant labor regulations require the Company’s PRC subsidiaries to pay the local labor and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government. The contributions to the plan are expensed as incurred. Employee social security and welfare benefits recognized as expense in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss amounted to $438,872 and $293,156 for the six months ended March 31, 2026 and 2025, respectively.

Recently Issued Accounting Pronouncements

The Company considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amended guidance improves the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development). The amended guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated financial statements.

F-16

In January 2025, the FASB issued ASU 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. This guidance amends the effective date of Update 2024-03 to clarify that all public business entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption of Update 2024-03 is permitted. The Company is currently in the process of evaluating the impact this amended guidance may have on the footnotes to its consolidated financial statements.

In November 2025, the FASB issued ASU 2025-08, Financial Instruments—Credit Losses (Topic 326): Purchased Loans. This update improves the decision usefulness of the financial reporting for acquired financial assets. The amendments require that purchased seasoned loans be accounted for using the gross-up approach, which will enhance comparability and consistency in the accounting for acquired financial assets. The amendments in this Update are effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. The Company is currently in the process of evaluating the impact this amended guidance may have on its consolidated financial statements.

In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities. This update improves U.S. GAAP by establishing authoritative guidance on the accounting for government grants received by business entities. For public business entities, the amendments are effective for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods. The Company is currently in the process of evaluating the impact this amended guidance may have on its consolidated financial statements.

In May 2026, the FASB issued ASU 2026-2, Environmental Credits and Environmental Credit Obligations (Topic 818). This Update provides recognition, measurement, presentation, and disclosure requirements for all entities that generate, purchase, or receive environmental credits or have a regulatory compliance obligation that may be settled with environmental credits. For public business entities, the amendments in this Update are effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. The Company is currently in the process of evaluating the impact this amended guidance may have on its consolidated financial statements.

Other accounting standards that have been issued by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent standards that are not anticipated to have an impact on or are unrelated to its consolidated financial condition, results of operations, cash flows or disclosures.

NOTE 3 — ACCOUNTS RECEIVABLE, NET

Accounts receivable consists of the following:

		As of
		March 31, 2026				September 30, 2025
		(Unaudited)
Accounts receivable		$	14,974,852			$	13,026,331
Less: allowance for credit loss			(18,797	)			(18,214	)
Accounts receivable, net		$	14,956,055			$	13,008,117

The Company’s accounts receivable primarily include the balance due from customers when the Company’s pharmaceutical products are sold and delivered to customers. As of the date of this report, approximately 38.0%, or $5.7 million, of the Company’s net accounts receivable balance as of March 31, 2026 has been subsequently collected.

F-17

Allowance for credit loss movement is as follows: 

		As of
		March 31, 2026				September 30, 2025
		(Unaudited)
Beginning balance		$	18,214			$	135,082
Reversal of allowance for credit loss			-				(113,454	)
Foreign currency translation adjustments			583				(3,414	)
Ending balance		$	18,797			$	18,214

NOTE 4 — INVENTORIES, NET

Inventories consist of the following: 

		As of
		March 31, 2026				September 30, 2025
		(Unaudited)
Raw materials		$	903,390			$	707,430
Finished goods			1,203,076				1,608,488
Inventories valuation allowance			(126,671	)			(122,739	)
Total inventories, net		$	1,979,795			$	2,193,179

Inventories valuation allowance movement is as follows:

		As of
		March 31, 2026				September 30, 2025
		(Unaudited)
Beginning balance		$	122,739			$	124,512
Foreign currency translation adjustments			3,932				(1,773	)
Ending balance		$	126,671			$	122,739

NOTE 5 — ADVANCE TO SUPPLIERS

Advances to suppliers consist of the following:

		As of
		March 31, 2026				September 30, 2025
		(Unaudited)
Advances to suppliers for purchase of goods		$	2,001,693			$	2,489,737
Advances to suppliers		$	2,001,693			$	2,489,737

Advances to suppliers represent prepayments made to suppliers to ensure continuous high-quality supplies and favorable purchase prices of raw materials.

F-18

NOTE 6 — OTHER RECEIVABLE

Other receivable consists of the following:

		As of
		March 31, 2026				September 30, 2025
		(Unaudited)
Deposit for acquisition company (1)		$	5,223,594			$	-
Prepaid value added tax			839,551				1,023,084
Prepayment for advertising			547,533				843,777
Prepayment for property, plant and equipment			259,698				136,185
Prepayment for research and development			28,994				99,733
Others			281,361				177,901
Total other receivable		$	7,180,731			$	2,280,680

(1) On June 17, 2026, the Company entered into a Share Purchase Agreement (the “SPA”) with Ms. Lu Shanshan (“Ms. Lu”), pursuant to which the Company agreed to acquire 100% of the issued shares (the “Target Shares”) of Best Praise International Limited (the “Target”) for a consideration of US$10,751,000, payable entirely through the issuance of 4,376,552 of the Company’s Class A ordinary shares (the “Consideration Shares”) to Ms. Lu or her designated recipients, subject to the terms and conditions set forth in the SPA. The Company prepaid $5,223,594 as a security deposit for the SPA as of March 31, 2026. As of the date of this report, 70% of the deposit, or $1,043,142, has been subsequently collected. The remaining 30% of the deposit, or $447,061, will be repaid within five business days after the Company completes the registration, transfer, and settlement of the Consideration Shares and Ms. Lu obtains ownership of the Consideration Shares.

NOTE 7 — SHORT-TERM INVSTMENTS

The Company’s short-term investments consist of bonds purchased from Hongkong and Shanghai Banking Corporation Limited (“HSBC”) with a term of three months and a maturity date of April 23, 2026. The bonds bear a fixed interest rate of 1.83% per annum. The movement of short-term investments is as follows:

		As of
		March 31, 2026				September 30, 2025
		(Unaudited)
Beginning balance		$	-			$	-
Add: purchase bond from HSBC			1,490,203				-
Ending balance		$	1,490,203			$	-

NOTE 8 — PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment, net, consists of the following:

		As of
		March 31, 2026				September 30, 2025
		(Unaudited)
Buildings		$	8,005,613			$	7,583,912
Machinery and equipment			2,456,548				2,262,271
Automobiles			85,776				83,113
Office and electric equipment			563,327				522,552
Construction-in-progress			27,940				35,458
Subtotal			11,139,204				10,487,306
Less: accumulated depreciation			(7,351,637	)			(6,903,753	)
Property, plant and equipment, net		$	3,787,567			$	3,583,553

Construction-in-progress consisted of design fee for the construction project, which amounted to $27,940 and $35,458 as of March 31, 2026 and September 30, 2025, respectively. Depreciation expense was $223,202 and $246,293 for the six months ended March 31, 2026 and 2025, respectively.

F-19

NOTE 9 — INTANGIBLE ASSETS, NET

Intangible assets, net consist of the following:

		As of
		March 31, 2026				September 30, 2025
		(Unaudited)
Land use rights		$	260,653			$	252,561
Trademark			218,179				200,169
Software			21,880				21,201
Total			500,712				473,931
Less: accumulated amortization			(190,962	)			(177,146	)
Intangible assets, net		$	309,750			$	296,785

Amortization expense was $8,015 and $23,346 for the six months ended March 31, 2026 and 2025, respectively.

Estimated future amortization expense for intangible assets is as follows:

Twelve months ending March 31,		Amortization expense
2027		$	48,849
2028			48,849
2029			48,849
2030			48,849
2031			48,849
Thereafter			65,505
		$	309,750

NOTE 10 — PREPAYMENT FOR CONSTRUCTION IN PROGRESS

On June 25, 2021, the Company entered into a construction contract with a sub-contractor, Jiangxi Chenyuan Construction Project Co., Ltd. (“Chenyuan”), pursuant to which, Chenyuan was engaged to construct four manufacturing factory buildings and an office building for the Company with a contract sum of RMB165 million (approximately $23.9 million). The construction work started on August 8, 2021, with an originally estimated completion date on August 7, 2023.

At beginning of the year ended December 31, 2024, due to resurgence of the COVID-19 pandemic, which resulted in lingering logistic disruption, material and labor shortage, and domestic travel restriction, the Company re-estimated that the completion date would be postponed to December 2024. However, during the year 2024, new information was discovered about the topographical and surface structures of the land, which required Chenyuan to re-conduct the geological survey. As a result, the construction progress was further delayed that cause the re-estimated completion date of December 2024 was not met.

In April 2025, Ministry of Emergency Management of PRC issued Specification for safety management of fine chemical enterprises, pursuant to which, enterprises should not set up employee dormitories within the factory premises. Because of this new regulation. the Company had to redesign the project, and the expected completion date of this construction project is further delayed to June 30, 2028. As of March 31, 2026, the Company had made a prepayment of approximately RMB69.2 million (approximately $10.0 million) to Chenyuan for land improvement, building foundation and the construction of the manufacturing factories.

F-20

During the year ended September 30, 2022, $414,251 (approximately RMB2.9 million) of the prepayment was re-classified to property, plant and equipment in the consolidated balance sheets. During the year ended September 30, 2025, management carried out impairment assessment on the prepayment for CIP project. The prepayment is refundable on-demand if the CIP project is aborted, management has assessed the recoverability of this prepayment to be approximately $8.9 million, and impairment loss of $481,109 was recognized in the profit or loss.

As of March 31, 2026, future additional capital expenditures on the CIP project are estimated to be approximately RMB95.8 million (equivalent to $13.9 million), of which approximately $3.6 million is required within the next 12 months. The Company currently plans to fund its ongoing CIP project construction through cash collected from accounts receivable and, if necessary, borrowings from PRC banks.

As of March 31, 2026, future minimum capital expenditures on the Company’s CIP project are estimated as follows:

Twelve months ending March 31,		Capital Expenditure on CIP
2027		$	3,624,239
2028			3,624,239
2029			5,443,607
2030			1,195,999
Total		$	13,888,084

NOTE 11 — PREPAYMENT FOR PURCHASE OF A PROPERTY

On May 6, 2021, the Company entered into a real estate property purchase agreement with a third party, Jiangxi Yueshang Investment Co., Ltd. (“Jiangxi Yueshang”), pursuant to which the Company agreed to purchase a certain residential apartment and commercial office space totaling 2,749.30 square meters, at a total purchase price of RMB32 million (approximately $4.6 million). Pursuant to the agreement, the Company was required to make a prepayment in the amount of 50% of the total purchase price, with 20% of the total purchase price payable upon the availability of a certificate of occupancy, and the remaining 30% of the total purchase price payable upon delivery of the property.

As of March 31, 2026, the Company had made a prepayment of RMB16 million (approximately $2.3 million) to Jiangxi Yueshang. Construction of the property was completed in May 2025. The Real Estate Ownership Certificate for the property is currently being obtained, and the remaining balance of RMB16 million (approximately $2.3 million) will be payable upon receipt thereof.

NOTE 12 — SHORT-TERM BANK LOANS

Short-term bank loans consist of the following:

				As of
		Note		March 31, 2026				September 30, 2025
				(Unaudited)
Short-term bank loans:
Jiangxi Luling Rural Commercial Bank (“LRC Bank”)		(1)		$	2,899,390			$	2,809,383
Bank of Communications Co., Ltd		(2)			1,449,696				1,404,692
Zhujiang Rural Bank		(3)			420,412				407,361
Beijing Bank		(4)			1,159,756				1,123,753
Huaxia Bank		(5)			724,848				702,346
Postal Savings Bank of China		(6)			724,848				702,346
Total short-term loans				$	7,378,950			$	7,149,881

F-21

(1) On March 3, 2025, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $702,346) as working capital for one year, with the maturity date on March 2, 2026. The fixed interest rate of the loan was 3.65% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid upon maturity.   On April 22, 2025, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,449,695) as working capital for one year, with the maturity date on April 21, 2026. The fixed interest rate of the loan was 3.60% per annum. Mr. Gang Lai and Universe Technology jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.     On May 16, 2025, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB5 million (equivalent to $702,346) as working capital for one year, with the maturity date on May 15, 2026. The fixed interest rate of the loan was 3.65% per annum. Mr. Gang Lai and Jiangxi Universe jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. The loan was fully repaid on February 28, 2026.   On February 28, 2026, a subsidiary of the Company, Universe Trade, signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,449,695) as working capital for one year, with the maturity date on February 27, 2027. The fixed interest rate of the loan was 3.65% per annum. Mr. Gang Lai, Universe Technology and Jiangxi Universe jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.

(2) On September 29, 2025, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,449,696) as working capital for one year, with the maturity date on September 29, 2026. The fixed interest rate of the loan was 3.00% per annum. Mr. Gang Lai, Universe Trade, and an unrelated third party, Jiangxi Province Financing Guarantee Group Co., Ltd., jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.

(3) On April 18, 2025, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with Zhujiang Rural Bank to borrow RMB2.9 million (equivalent to $420,412) as working capital for one year, with the maturity date on April 18, 2026. The fixed interest rate of the loan was 5.00% per annum. The Company pledged certain trademarks owned by it as collateral to guarantee this loan.

(4) On September 12, 2025, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Beijing Bank to borrow RMB8 million (equivalent to $1,159,756) as working capital for one year, with the maturity date on September 12, 2026. The fixed interest rate of the loan was 3.70% per annum. Mr. Gang Lai and Universe Trade jointly signed guarantee agreements with Beijing Bank to provide credit guarantee for this loan.

(5) On June 27, 2025, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Huaxia Bank to borrow RMB5 million (equivalent to $724,848) as working capital for one year, with the maturity date on June 27, 2026. The fixed interest rate of the loan was 3.70% per annum. Mr. Gang Lai provided credit guarantee for this loan.

(6) On July 17, 2025, a subsidiary of the Company, Jiangxi Universe, entered into a loan agreement with Postal Savings Bank of China to borrow RMB5 million (equivalent to $724,848) as working capital for one year, with the maturity date on July 17, 2026. The fixed interest rate of the loan was 3.11% per annum. Mr. Gang Lai provided credit guarantee for this loan.

F-22

NOTE 13 — LONG-TERM BANK LOANS

Long-term bank loans consist of the following:

				As of
		Note		March 31, 2026				September 30, 2025
				(Unaudited)
Long-term bank loans:
LRC Bank		(1)		$	2,174,543			$	2,107,038
Less: current portion of long-term bank loans					-				(2,107,038	)
Non-current portion of long-term bank loans				$	2,174,543			$	-

(1) On November 23, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB15 million (equivalent to approximately $2.1 million) as working capital for two years, with the maturity date on November 14, 2025. The fixed interest rate of the loan was 3.95% per annum. The Company pledged buildings of Jiangxi Universe as collateral to guarantee this loan. The loan was fully repaid upon maturity.

On November 4, 2025, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB15 million (equivalent to approximately $2.2 million) as working capital for three years, with the maturity date on November 3, 2028. The fixed interest rate of the loan was 3.45% per annum. The Company pledged buildings of Jiangxi Universe as collateral to guarantee this loan. Mr. Gang Lai, Ms. Lin Yang and Universe Technology jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan.

For the above-mentioned loans, the Company recorded a total interest expense of $159,395 and $289,385 for the six months ended March 31, 2026 and 2025, respectively.

NOTE 14 — RELATED PARTY TRANSACTIONS

(a) Nature of relationships with related parties

Name		Relationship with the Company
Mr. Gang Lai		Chief Executive Officer and chairman of the Company’s Board of Directors
Ms. Lin Yang		Chief Financial Officer of the Company

(b) Due to related parties

		As of
Name		March 31, 2026				September 30, 2025
		(Unaudited)
Mr. Gang Lai		$	157,207			$	446,460
Ms. Lin Yang			87				85
Total due to related parties		$	157,294			$	446,545

As of March 31, 2026, the balance due to related parties mainly consisted of advances from Mr. Gang Lai, the Company’s chief executive officer and the chairman of the board of directors for working capital purposes during the Company’s normal course of business, as well as payment of expenses made by Ms. Lin Yang on behalf of the Company. These advances are unsecured, non-interest bearing and due on demand.

F-23

(c) Loan guarantee provided by related parties

In connection with the Company’s bank borrowings from commercial banks in China, Mr. Gang Lai and Ms. Lin Yang signed guarantee agreements with these banks to provide credit guarantee for the Company’s certain loans (see Note 12 and 13).

NOTE 15 — CONCENTRATIONS

A majority of the Company’s revenue and expense transactions are denominated in RMB, and a significant portion of the Company’s and its subsidiaries’ assets and liabilities are denominated in RMB. RMB is not freely convertible into foreign currencies. In the PRC, certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange rates set by the People’s Bank of China (“PBOC”). Remittances in currencies other than RMB by the Company in China must be processed through the PBOC or other China foreign exchange regulatory bodies, which require certain supporting documentation in order to effect the remittance. Each bank account is insured by the PRC government authority up to a maximum limit of RMB500,000 (equivalent to approximately $72,485). To limit exposure to credit risk relating to deposits, the Company primarily places cash and cash equivalents with large financial institutions in China that management believes are of high credit quality, and the Company also continually monitors their creditworthiness.

The Company’s operations are carried out in China. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, as well as by the general state of the PRC’s economy. In addition, the Company’s business may be influenced by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other factors.

As of March 31, 2026 and September 30, 2025, $11,790,217 and $9,608,188 of the Company’s cash, respectively, was on deposit at financial institutions in the PRC. For the six months ended March 31, 2026 and 2025, the Company’s substantial assets were located in the PRC and all of the Company’s revenues were derived from its subsidiaries located in the PRC.

For the six months ended March 31, 2026 and 2025, no single customer accounted for more than 10% of the Company’s total revenue. The Company’s top 10 customers accounted in the aggregate for 28.6% and 18.3% of the Company’s total revenue for the six months ended March 31, 2026 and 2025, respectively.

Sales of one of the Company’s major products, Guben Yanling Pill, accounted for 40.0% of the Company’s total revenue for each of the six months ended March 31, 2026 and 2025.

As of March 31, 2026 and September 30, 2025, no customer accounted for more than 10% of the total accounts receivable balance.

For the six months ended March 31, 2026 and 2025, one supplier accounted for 19.2% and 45.3% of the total purchases, respectively.

As of March 31, 2026 and September 30, 2025, no supplier accounted for more than 10% of the total accounts payable balance.

NOTE 16 — SHAREHOLDERS’ EQUITY

Ordinary Shares

Universe INC was incorporated under the laws of the Cayman Islands on December 11, 2019. The original authorized number of ordinary shares upon incorporation was 50,000 shares with par value of US$1.00 per share and 50,000 shares were issued. On August 7, 2020, the Company amended its Memorandum of Association to increase the authorized number of shares to 100,000,000 shares with par value of $0.003125 per share, and subdivide the original issued shares from 50,000 shares at par value of $1.00 per share to 16,000,000 ordinary shares with par value of $0.003125 per share. As a result of this forward split of the outstanding ordinary shares at a ratio of 320-for-1 share, a total of 16,000,000 shares were issued and outstanding after the split. The issuance of these 16,000,000 shares is considered as a part of the Reorganization of the Company, which was retroactively applied as if the transaction occurred at the beginning of the period presented.

F-24

Increased authorized share capital and share consolidation

On July 3, 2023, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:

(a) with immediate effect, to increase the Company’s authorized share capital from US$312,500 divided into 90,000,000 ordinary shares of par value US$0.003125 each and 10,000,000 preferred shares of par value US$0.003125 each, to US$3,125,000 divided into 900,000,000 ordinary shares of par value US$0.003125 each and 100,000,000 preferred shares of par value US$0.003125 each;

(b) that, conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of the Company may determine, the authorized, issued and outstanding shares of the Company be consolidated by consolidating each 10 shares of the Company, or such lesser whole share amount as the board of directors may determine in its sole discretion, such amount not to be less than 2, into 1 share of the Company, with such consolidated shares having the same rights and being subject to the same restrictions (save as to nominal value) as the then existing shares of par value US$0.003125 each in the capital of the Company; and

(c) that, upon the effectiveness of the 2023 Share Consolidation, the Company adopt amended and restated articles of association, in substantially the form set out in Annex B in the proxy statement dated May 24, 2023, in substitution for and to the exclusion of, the memorandum of association of the Company in effect immediately prior to effectiveness of the 2023 Share Consolidation.

The board of directors of the Company resolved to effect the 2023 Share Consolidation on July 27, 2023 with the authorized, issued and outstanding shares to be consolidated on a six (6) for one (1) ratio, which had the effect of reducing the number of: (a) authorized ordinary shares from 900,000,000 ordinary shares with a par value of US$0.003125 per share to 150,000,000 ordinary shares with a par value of US$0.01875 per share; (b) issued and outstanding ordinary shares from 21,750,000 ordinary shares with a par value of US$0.003125 per share to 3,625,000 ordinary shares with a par value of US$0.01875 per share; and (c) authorized preferred shares from 100,000,000 preferred shares with a par value of US$0.003125 per share to 16,666,666.6666 preferred shares with a par value of US$0.01875 per share.

On July 15, 2024, the Company closed its self-underwritten public offering of 20,000,000 ordinary shares, par value $0.01875 per share. The ordinary shares were priced at $1.25 per share. The Company raised a total of $25 million through that offering, before deducting offering-related expenses, and net proceeds of $24.625 million.

On September 27, 2024, the Company held an annual general meeting of shareholders at which shareholders, among other things, resolved:

(a) with immediate effect, to increase the Company’s authorized share capital from US$3,125,000 divided into 150,000,000 ordinary shares of par value US$0.01875 each and 16,666,666.6666 preferred shares of par value US$0.01875 each, to US$140,625,000 divided into 6,750,000,000 ordinary shares of par value US$0.01875 each and 750,000,000 preferred shares of par value US$0.01875 each;

(b) that, subject to and immediately following the Authorized Share Capital Increase being effected, the Company adopt an amended and restated memorandum of association in substitution for, and to the exclusion of, the Company’s existing memorandum of association, to reflect the Authorized Share Capital Increase; and

(c) that, conditional upon the approval of the board of directors of the Company in its sole discretion, with effect as of the date the board of directors of the Company may determine, the authorized, issued, and outstanding shares of the Company be consolidated by consolidating each 15 Shares of the Company, or such lesser whole share amount as the board of directors of the Company may determine in its sole discretion, such amount not to be less than 2, into 1 Share of the Company, with such consolidated Shares having the same rights and being subject to the same restrictions (save as to nominal value) as the existing Shares of such class as set out in the Company’s memorandum and articles of association.

F-25

On November 12, 2024, the Company effected a share consolidation of 15 ordinary shares with par value of US$0.01875 per share each in the Company’s issued and unissued share capital into one (1) ordinary share with par value of US$0.28125. All fractional shares were rounded up to the whole number of shares. Immediately following the Share Consolidation, the authorized share capital of the Company was US$140,625,000 divided into 450,000,000 ordinary shares, par value US$0.28125 per share and 50,000,000 preferred shares, par value US$0.28125 per share.

On March 24, 2025, the Company effected a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company’s issued and unissued share capital into one ordinary share with par value of US$11.25. All fractional shares were rounded up to the whole number of shares. Immediately following the Share Consolidation, the authorized share capital of the Company was US$140,625,000 divided into 11,250,000 ordinary shares, par value US$11.25 per share and 1,250,000 preferred shares, par value US$11.25 per share.

On September 3, 2025, the Company held an annual general meeting of shareholders at which shareholders, resolved as a special resolution that, subject to and conditional upon, amongst other things: (i) approval from the Grand Court of the Cayman Islands (the “Court”) of the Capital Reduction (as defined below); (ii) registration by the Registrar of Companies of the Cayman Islands of the order of the Court confirming the Capital Reduction and the minute approved by the Court containing the particulars required under the Companies Act (Revised) (the “Act”) in respect of the Capital Reduction and compliance with any conditions the Court may impose; (iii) compliance with the relevant procedures and requirements under the applicable laws of the Cayman Islands to effect the Capital Reduction; and (iv) obtaining of all necessary approvals from the regulatory authorities or otherwise as may be required in respect of the Capital Reduction, with effect from the date on which these conditions are fulfilled:

a) the par value of each issued Ordinary Share of par value US$11.25 each in the share capital of the Company be reduced to par value US$0.00001 each (the “Capital Reduction”) by cancelling the paid-up capital to the extent of US$11.24999 on each of the then issued Ordinary Shares of par value US$11.25 each;

b) the credit arising from the Capital Reduction be transferred to a distributable reserve account of the Company which may be utilized by the Company as the board of directors of the Company may deem fit and as permitted under the Act, the amended and restated memorandum of association adopted by special resolution passed on 1 March 2025 and unanimous written director resolutions passed on 20 February 2025 and made effective on 17 March 2025 (the “Existing Memorandum”), the second amended and restated articles of association of the Company adopted by special resolution passed on 23 September 2022 (the “Existing Articles”), and all relevant applicable laws, including, without limitation, eliminating or setting off any accumulated losses of the Company (if any) from time to time;

c) immediately following the Capital Reduction, pursuant to section 13 of the Act and article 8.1(d) of the Existing Articles, each of the authorized but unissued Ordinary Shares of par value US$11.25 each be sub-divided into 1,125,000 ordinary shares of par value US$0.00001 each (the “Sub-division”);

d) immediately following the Capital Reduction and the Sub-division, the authorized share capital of the Company be altered by the cancellation of: (i) the 1,250,000 unissued Preferred Shares of par value US$11.25 each; and (ii) 12,020,495,313,338 of the unissued ordinary shares of par value US$0.00001 each, such that the authorized share capital is altered:

from US$134,287,453.13338 divided into: (i) 12,022,495,313,338 ordinary shares of par value US$0.00001 each; and (ii) 1,250,000 Preferred Shares of par value US$11.25 each;

to US$20,000 divided into 2,000,000,000 ordinary shares of par value US$0.00001 each

(the “Capital Alteration”);

F-26

e) immediately following the Capital Alteration:

a. the authorized and issued share capital of the Company be divided into two separate classes as follows:

i. US$18,000 divided into 1,800,000,000 class A ordinary shares of par value US$0.00001 each (the “Class A Ordinary Shares”); and

ii. US$2,000 divided into 200,000,000 class B ordinary shares of par value US$0.00001 each (the “Class B Ordinary Shares” and, together with the Class A Ordinary Shares, the “New Share Classes”),

it being noted that the terms of, and rights attaching to the New Share Classes will be materially identical to the existing ordinary shares of par value US$0.00001 each in the capital of the Company save that the Class B Ordinary Shares: (i) shall have 100 times the voting rights per share of Class A Ordinary Shares; and (ii) shall be convertible into Class A Ordinary Shares;

b. the issued shares in the Company outstanding following the Capital Alteration be re-designated, as follows:

i. the 559,868 ordinary shares of par value US$0.00001 each held by Cede & Co be re-designated as 559,868 Class A Ordinary Shares;

ii. the 1 ordinary share of par value US$0.00001 held by Christopher Lin be re-designated as 1 Class A Ordinary Share;

iii. the 1 ordinary share of par value US$0.00001 held by Michael Olson be re-designated as 1 Class A Ordinary Share;

iv. the 1 ordinary share of par value US$0.00001 held by Daniel J Sleiman be re-designated as 1 Class A Ordinary Share; and

v. the 3,467 ordinary shares of par value US$0.00001 each held by Sununion Holding Group Limited be re-designated as 3,467 Class B Ordinary Shares,

(steps (a) to (e) (inclusive) above shall be collectively referred to as the “Capital Reorganization”),

f) any one or more of the directors of the Company be and is/are hereby authorized to do all such acts and things and execute all such documents, which are in connection with and/or ancillary to the Capital Reorganization and any of the foregoing steps and of administrative nature, on behalf of the Company, including under seal where applicable, as they consider necessary, desirable or expedient to give effect to the foregoing arrangements for the Capital Reorganization and (where applicable) to aggregate all fractional Class A Ordinary Shares and/or Class B Ordinary Shares and sell them for the benefit of the Company.”

On February 13, 2026, the dual-class share structure became effective on the Nasdaq Capital Market, and the Company’s authorized share capital was changed to US$20,000 divided into 1,800,000,000 class A ordinary shares of par value US$0.00001 each (the “Class A Ordinary Shares”) and 200,000,000 class B ordinary shares of par value US$0.00001 each.

As of March 31, 2026, the Company had a total of 563,338 class A ordinary shares issued and outstanding, no class B ordinary shares issued and outstanding.

F-27

Underwriter warrants

In connection with the Company’s initial public offering (the “IPO”), the Company agreed to issue warrants to the underwriter, for a nominal consideration of $0.001 per warrant, to purchase 300,000 ordinary shares of the Company (equal to 6% of the total number of ordinary shares sold in the IPO, excluding any ordinary shares sold pursuant to the over-allotment option) (the “Underwriter Warrants”). The Underwriter Warrants had a term of five (5) years, with each warrant exercisable for 1/90 of one ordinary share at an exercise price of $495 per share, as adjusted to reflect the Company’s share consolidations. The Underwriter Warrants were exercisable for cash or on a cashless basis and expired in March 2026. On December 6, 2024, the Company entered into a securities purchase agreement with certain purchasers pursuant to which the Company agreed to issue 18,750,000 common warrants to purchase an aggregate of 18,750,000 ordinary shares at an exercise price of $32.00 per ordinary share. Each common warrant is exercisable from the date of issuance until the fifth anniversary thereof and will expire in December 2029. Management determined that the Underwriter Warrants and the common warrants each meet the requirements for equity classification under ASC 815-40, as each is indexed to the Company’s own ordinary shares. As of March 31, 2026, the common warrants remained issued and outstanding, and none had been exercised. For the six months ended March 31, 2026 and 2025, the Underwriter Warrants and the common warrants were antidilutive and, accordingly, were excluded from the diluted earnings per share calculation under the treasury stock method.

Statutory reserve and restricted net assets

The Company’s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. The payment of dividends by entities organized in China is subject to limitations, procedures, and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China.

The Company is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (“PRC GAAP”). Appropriations to the statutory surplus reserve are required to be at least 10% of the after-tax net income determined in accordance with PRC GAAP until the reserve is equal to 50% of the entity’s registered capital. Appropriations to the discretionary surplus reserve are made at the discretion of the board of directors. The statutory reserve may be applied against prior year losses, if any, and may be used for general business expansion and production, or to increase registered capital, but is not distributable as cash dividends.

Relevant PRC laws and regulations restrict the Company’s PRC subsidiaries from transferring a portion of their net assets, equivalent to their statutory reserves and their share capital, to the Company in the form of loans, advances, or cash dividends. Only PRC entities’ accumulated profits may be distributed as dividends to the Company without the consent of a third party. As of March 31, 2026 and September 30, 2025, the restricted amounts as determined pursuant to PRC statutory laws totaled $2,439,535, and total restricted net assets amounted to $34,476,310 and $32,495,275, respectively.

NOTE 17 — COMMITMENTS AND CONTINGENCIES

From time to time, the Company may become a party to various legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. For the six months ended March 31, 2026 and 2025, the Company did not have any material legal claims or litigation that, individually or in aggregate, could have a material adverse impact on the Company’s consolidated financial position, results of operations and cash flows.

The Company has an ongoing CIP project associated with the construction of a new manufacturing facility. As of March 31, 2026, future minimum capital expenditures on the Company’s CIP project amounted to approximately $13.9 million, among which, approximately $3.6 million is required for the next 12 months from the date of this report (see Note 10).

On May 6, 2021, the Company entered into a real estate property purchase agreement with Jiangxi Yueshang, pursuant to which Jiangxi Yueshang agreed to sell, and the Company agreed to purchase, certain residential apartments and commercial office space totaling 2,749.30 square meters for a total purchase price of RMB32 million (approximately $4.6 million). As of March 31, 2026, the Company had made a prepayment of RMB16 million (approximately $2.3 million) to Jiangxi Yueshang. The Real Estate Ownership Certificate for the property is currently being processed, and the remaining balance of RMB16 million (approximately $2.3 million) will be payable upon receipt of the Real Estate Ownership Certificate (see Note 11).

F-28

NOTE 18 — SUBSEQUENT EVENTS

On April 14, 2026, the Company adopted its 2026 Equity Incentive Plan (the “2026 Equity Incentive Plan”), which provides for the grant of various equity-based awards with respect to a maximum number of 84,500 ordinary shares, par value US$0.00001 per share, of the Company (whether Class A ordinary shares, Class B ordinary shares, or a combination thereof) available for issuance thereunder. This maximum amount is subject to increase on a yearly basis pursuant to the evergreen provision in the equity incentive plan.

On May 5, 2026, the compensation committee of the Company’s Board of Directors (the “Board”) and the Board, as administrator of the 2026 Equity Incentive Plan, approved the grant of an aggregate of 71,890 Class A ordinary shares and 12,610 Class B ordinary shares of the Company to Mr. Gang Lai, under the 2026 Equity Incentive Plan, as compensation for Mr. Lai’s past services to the Company. Each Class B ordinary share is convertible into one Class A ordinary share on a one-for-one basis. The shares were issued on May 7, 2026.

On June 17, 2026, the Company entered into a Share Purchase Agreement (the “SPA”) with Ms. Lu Shanshan (“Ms. Lu”), pursuant to which the Company agreed to acquire 100% of the issued shares (the “Target Shares”) of Best Praise International Limited (the “Target”) for a consideration of US$10,751,000, payable entirely through the issuance of 4,376,552 of the Company’s Class A ordinary shares (the “Consideration Shares”) to Ms. Lu or her designated recipients, subject to the terms and conditions set forth in the SPA.

NOTE 19 — FINANCIAL INFORMATION OF THE PARENT COMPANY

Pursuant to the requirements of Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X, the financial information of the parent company shall be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with such requirement and concluded that it was applicable to the Company as the restricted net assets of the Company’s subsidiaries exceeded 25% of the consolidated net assets of the Company. Therefore, the financial statements for the parent company are included herein.

For purposes of the above test, restricted net assets of consolidated subsidiaries shall mean that amount of the Company’s proportionate share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the consent of a third party.

The financial information of the parent company has been prepared using the same accounting policies as set out in the Company’s unaudited condensed consolidated financial statements except that the parent company used the equity method to account for investment in its subsidiaries. Such investment is presented on the balance sheets as “Investment in subsidiaries” and the respective profit or loss as “Equity in earnings of subsidiaries” on the unaudited condensed ‘consolidated statements of operations and comprehensive loss.

The footnote disclosures contain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the unaudited condensed consolidated financial statements of the Company. Certain information and footnote disclosures normally included in unaudited condensed financial statements prepared in accordance with U.S GAAP have been or omitted.

As of March 31, 2026 and September 30, 2025, there were no material contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those which have been separately disclosed in the unaudited condensed consolidated financial statements, if any.

F-29

UNIVERSE PHARMACEUTICALS INC AND SUBSIDIARIES

PARENT COMPANY BALANCE SHEETS

		As of
		March 31, 2026				September 30, 2025
		(Unaudited)
ASSETS
Cash		$	15,736,152			$	23,938,610
Other receivable			5,223,594				-
Due from related parties			5,595,883				5,638,387
Due from subsidiaries			13,545,139				11,155,749
Total current assets			40,100,768				40,732,746
Non-current asset
Investment in subsidiaries		$	15,544,295			$	15,396,764
Total assets		$	55,645,063			$	56,129,510
LIABILITIES AND SHAREHOLDERS’ EQUITY
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY
Class A ordinary shares, $0.00001 par value, 1,800,000,000 shares authorized, 563,338 shares issued and outstanding as of March 31, 2026 * Ordinary shares, $11.25 par value, 2,000,000,000 shares authorized, 563,338 shares issued and outstanding as of September 30, 2025			6				6,337,553
Class B ordinary shares, $0.00001 par value, 200,000,000 shares authorized, none issued and outstanding as of March 31, 2026 and September 30, 2025			-				-
Additional paid-in capital			69,347,114				63,009,567
Accumulated deficit			(12,958,901	)			(11,404,088	)
Accumulated other comprehensive loss			(743,156	)			(1,813,522	)
Total shareholders’ equity			55,645,063				56,129,510
Total liabilities and shareholders’ equity		$	55,645,063			$	56,129,510

* The dual-class share structure became effective on February 13, 2026.

F-30

UNIVERSE PHARMACEUTICALS INC AND SUBSIDIARIES

PARENT COMPANY STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 (UNAUDITED)

		For the Six Months Ended March 31,
		2026				2025
Operating costs and expenses:
General and administrative expenses		$	(292,948	)		$	(1,835,286	)
Other income (expenses):
Interest income			60				-
Other expenses			(33,893	)			(727,331	)
Equity in loss of subsidiaries			(1,228,032	)			(722,138	)
Net loss			(1,554,813	)			(3,284,755	)
Foreign currency translation adjustments			1,070,366				(2,033,233	)
Comprehensive loss attributable to the Company		$	(484,447	)		$	(5,317,988	)

F-31

UNIVERSE PHARMACEUTICALS INC AND SUBSIDIARIES

PARENT COMPANY STATEMENTS OF CASH FLOWS

 (UNAUDITED)

		For the Six Months Ended March 31,
		2026				2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$	(1,554,813	)		$	(3,284,755	)
Adjustments to reconcile net cash flows from operating activities:
Equity in earnings of subsidiary			1,228,032				722,138
Changes in operating assets and liabilities:
Other receivable			(5,223,594	)			1,377,873
Due from related parties			42,504				-
Due to related parties			-				137,814
Other payable			-				7,882
Accrued expense			-				(49,475	)
Net cash used in operating activities			(5,507,871	)			(1,088,523	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in subsidiaries			-				(9,100,000	)
Net cash used in investing activities			-				(9,100,000	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of ordinary shares							15,000,000
Cash repayment from subsidiaries			(2,389,390	)			(588,780	)
Net cash (used in) provided by financing activities			(2,389,390	)			14,411,220
EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH			(305,197	)			(437,377	)
CHANGES IN CASH			(8,202,458	)			3,785,320
CASH, beginning of period			23,938,610				25,058,414
CASH, end of period		$	15,736,152			$	28,843,734

F-32

1 1 On November 23, 2023, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB15 million (equivalent to approximately $2.1 million) as working capital for two years, with the maturity date on November 14, 2025. The fixed interest rate of the loan was 3.95% per annum. The Company pledged buildings of Jiangxi Universe as collateral to guarantee this loan. The loan was fully repaid upon maturity. On November 4, 2025, a subsidiary of the Company, Jiangxi Universe, signed a loan agreement with LRC Bank to borrow RMB15 million (equivalent to approximately $2.2 million) as working capital for three years, with the maturity date on November 3, 2028. The fixed interest rate of the loan was 3.45% per annum. The Company pledged buildings of Jiangxi Universe as collateral to guarantee this loan. Mr. Gang Lai, Ms. Lin Yang and Universe Technology jointly signed guarantee agreements with LRC Bank to provide credit guarantee for this loan. 0001809616 false 2026-03-31 2026 Q2 --09-30 0001809616 2025-10-01 2026-03-31 0001809616 2026-03-31 0001809616 2025-09-30 0001809616 us-gaap:RelatedPartyMember 2026-03-31 0001809616 us-gaap:RelatedPartyMember 2025-09-30 0001809616 us-gaap:CommonClassAMember 2026-03-31 0001809616 us-gaap:CommonClassAMember 2025-09-30 0001809616 us-gaap:CommonClassBMember 2026-03-31 0001809616 us-gaap:CommonClassBMember 2025-09-30 0001809616 2024-10-01 2025-03-31 0001809616 us-gaap:CommonStockMember 2024-09-30 0001809616 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001809616 upc:StatutoryReservesMember 2024-09-30 0001809616 us-gaap:RetainedEarningsMember 2024-09-30 0001809616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001809616 2024-09-30 0001809616 us-gaap:CommonStockMember 2024-10-01 2025-03-31 0001809616 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2025-03-31 0001809616 upc:StatutoryReservesMember 2024-10-01 2025-03-31 0001809616 us-gaap:RetainedEarningsMember 2024-10-01 2025-03-31 0001809616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-01 2025-03-31 0001809616 us-gaap:CommonStockMember 2025-03-31 0001809616 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001809616 upc:StatutoryReservesMember 2025-03-31 0001809616 us-gaap:RetainedEarningsMember 2025-03-31 0001809616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001809616 2025-03-31 0001809616 us-gaap:CommonStockMember 2025-09-30 0001809616 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001809616 upc:StatutoryReservesMember 2025-09-30 0001809616 us-gaap:RetainedEarningsMember 2025-09-30 0001809616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001809616 us-gaap:CommonStockMember 2025-10-01 2026-03-31 0001809616 us-gaap:AdditionalPaidInCapitalMember 2025-10-01 2026-03-31 0001809616 upc:StatutoryReservesMember 2025-10-01 2026-03-31 0001809616 us-gaap:RetainedEarningsMember 2025-10-01 2026-03-31 0001809616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-10-01 2026-03-31 0001809616 us-gaap:CommonStockMember 2026-03-31 0001809616 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001809616 upc:StatutoryReservesMember 2026-03-31 0001809616 us-gaap:RetainedEarningsMember 2026-03-31 0001809616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001809616 upc:UniverseIncMember 2025-10-01 2026-03-31 0001809616 upc:UniverseIncMember 2026-03-31 0001809616 upc:UniverseHKMember 2025-10-01 2026-03-31 0001809616 upc:JiangxiUniverseMember 2025-10-01 2026-03-31 0001809616 upc:UniverseTradeMember 2026-03-31 0001809616 upc:UniverseTechnologyMember 2026-03-31 0001809616 upc:NasdaqGlobalMarketMember us-gaap:IPOMember upc:ReorganizationMember 2021-03-25 2021-03-25 0001809616 upc:NasdaqGlobalMarketMember us-gaap:IPOMember upc:ReorganizationMember 2021-03-25 0001809616 upc:NasdaqGlobalMarketMember upc:ReorganizationMember 2021-03-25 0001809616 upc:NasdaqGlobalMarketMember us-gaap:OverAllotmentOptionMember upc:ReorganizationMember 2021-03-29 2021-03-29 0001809616 upc:NasdaqGlobalMarketMember us-gaap:IPOMember upc:ReorganizationMember 2021-03-29 2021-03-29 0001809616 srt:MinimumMember upc:ReorganizationMember 2023-07-03 0001809616 srt:MinimumMember us-gaap:CommonStockMember upc:ReorganizationMember 2023-07-03 0001809616 srt:MinimumMember us-gaap:PreferredStockMember upc:ReorganizationMember 2023-07-03 0001809616 srt:MaximumMember upc:ReorganizationMember 2023-07-03 0001809616 srt:MaximumMember us-gaap:PreferredStockMember upc:ReorganizationMember 2023-07-03 0001809616 upc:TwoThousandTwentyThreeShareConsolidationMember us-gaap:CommonStockMember upc:ReorganizationMember 2023-07-03 0001809616 srt:MaximumMember srt:DirectorMember upc:TwoThousandTwentyThreeShareConsolidationMember us-gaap:CommonStockMember upc:ReorganizationMember 2023-07-27 0001809616 upc:ShareholdersMember srt:MinimumMember srt:DirectorMember upc:TwoThousandTwentyThreeShareConsolidationMember upc:ReorganizationMember 2023-07-27 0001809616 upc:ShareholdersMember srt:MinimumMember srt:DirectorMember upc:TwoThousandTwentyThreeShareConsolidationMember upc:CommonStockOneMember upc:ReorganizationMember 2023-07-27 0001809616 srt:MaximumMember srt:DirectorMember upc:TwoThousandTwentyThreeShareConsolidationMember upc:CommonStockOneMember upc:ReorganizationMember 2023-07-27 0001809616 srt:MinimumMember srt:DirectorMember upc:TwoThousandTwentyThreeShareConsolidationMember upc:ReorganizationMember 2023-07-27 0001809616 srt:DirectorMember upc:TwoThousandTwentyThreeShareConsolidationMember us-gaap:PreferredStockMember upc:ReorganizationMember 2023-07-27 0001809616 srt:DirectorMember upc:TwoThousandTwentyThreeShareConsolidationMember upc:ReorganizationMember 2023-07-27 0001809616 us-gaap:CommonStockMember upc:SelfUnderwrittenPublicOfferingMember upc:ReorganizationMember 2024-07-15 2024-07-15 0001809616 us-gaap:CommonStockMember upc:SelfUnderwrittenPublicOfferingMember upc:ReorganizationMember 2024-07-15 0001809616 upc:SelfUnderwrittenPublicOfferingMember upc:ReorganizationMember 2024-07-15 0001809616 upc:SelfUnderwrittenPublicOfferingMember upc:ReorganizationMember 2024-07-15 2024-07-15 0001809616 upc:ShareholdersMember srt:MaximumMember upc:AuthorizedShareCapitalIncreaseMember upc:ReorganizationMember 2024-09-27 0001809616 upc:ShareholdersMember srt:MaximumMember upc:AuthorizedShareCapitalIncreaseMember us-gaap:CommonStockMember upc:ReorganizationMember 2024-09-27 0001809616 upc:ShareholdersMember srt:MaximumMember upc:AuthorizedShareCapitalIncreaseMember us-gaap:PreferredStockMember upc:ReorganizationMember 2024-09-27 0001809616 upc:ShareholdersMember upc:AuthorizedShareCapitalIncreaseMember us-gaap:PreferredStockMember upc:ReorganizationMember 2024-09-27 0001809616 upc:AuthorizedShareCapitalIncreaseMember upc:ReorganizationMember 2024-09-27 0001809616 srt:BoardOfDirectorsChairmanMember upc:AuthorizedShareCapitalIncreaseMember us-gaap:CommonStockMember upc:ReorganizationMember 2024-09-27 2024-09-27 0001809616 upc:ShareholdersMember upc:AuthorizedShareCapitalIncreaseMember us-gaap:CommonStockMember upc:ReorganizationMember 2024-09-27 0001809616 upc:AuthorizedShareCapitalIncreaseMember us-gaap:PreferredStockMember upc:ReorganizationMember 2024-09-27 0001809616 upc:ShareholdersMember upc:TwoThousandTwentyFourShareConsolidationMember us-gaap:CommonStockMember upc:ReorganizationMember 2024-11-12 0001809616 upc:ShareholdersMember upc:TwoThousandTwentyFourShareConsolidationMember upc:ReorganizationMember 2024-11-12 0001809616 upc:TwoThousandTwentyFourShareConsolidationMember us-gaap:CommonStockMember upc:ReorganizationMember 2024-11-12 0001809616 upc:TwoThousandTwentyFourShareConsolidationMember upc:ReorganizationMember 2024-11-12 0001809616 upc:TwoThousandTwentyFourShareConsolidationMember us-gaap:PreferredStockMember upc:ReorganizationMember 2024-11-12 0001809616 upc:ShareholdersMember upc:TwoThousandTwentyFiveShareConsolidationMember us-gaap:CommonStockMember upc:ReorganizationMember 2025-03-24 0001809616 upc:TwoThousandTwentyFiveShareConsolidationMember upc:ReorganizationMember 2025-03-24 0001809616 upc:TwoThousandTwentyFiveShareConsolidationMember us-gaap:CommonStockMember upc:ReorganizationMember 2025-03-24 0001809616 upc:CapitalReductionMember us-gaap:CommonStockMember upc:ReorganizationMember 2025-09-03 0001809616 upc:CapitalReductionMember upc:ReorganizationMember 2025-09-03 0001809616 upc:ReorganizationMember 2025-09-03 0001809616 upc:SubDivisionMember upc:ReorganizationMember 2025-09-03 0001809616 upc:CapitalAlterationMember upc:ReorganizationMember 2025-09-03 0001809616 upc:CapitalAlterationMember us-gaap:CommonStockMember upc:ReorganizationMember 2025-09-03 0001809616 us-gaap:CommonClassAMember upc:ReorganizationMember 2025-09-03 0001809616 upc:CapitalAlterationMember us-gaap:CommonClassAMember upc:ReorganizationMember 2025-09-03 0001809616 us-gaap:CommonClassBMember upc:ReorganizationMember 2025-09-03 0001809616 upc:CapitalAlterationMember us-gaap:CommonClassBMember upc:ReorganizationMember 2025-09-03 0001809616 upc:NewShareClassesMember us-gaap:CommonClassBMember upc:ReorganizationMember 2025-09-03 0001809616 upc:CapitalAlterationMember upc:NewShareClassesMember us-gaap:CommonClassAMember upc:ReorganizationMember 2025-09-03 2025-09-03 0001809616 upc:ReorganizationMember upc:CedeCoMember 2025-09-03 0001809616 us-gaap:CommonClassAMember upc:ReorganizationMember upc:CedeCoMember 2025-09-03 0001809616 upc:ReorganizationMember upc:ChristopherLinMember 2025-09-03 0001809616 us-gaap:CommonClassAMember upc:ReorganizationMember upc:ChristopherLinMember 2025-09-03 0001809616 upc:ReorganizationMember upc:MichaelOlsonMember 2025-09-03 0001809616 us-gaap:CommonClassAMember upc:ReorganizationMember upc:MichaelOlsonMember 2025-09-03 0001809616 upc:ReorganizationMember upc:DanielJSleimanMember 2025-09-03 0001809616 upc:CapitalAlterationMember us-gaap:CommonClassAMember upc:ReorganizationMember upc:DanielJSleimanMember 2025-09-03 0001809616 upc:ReorganizationMember upc:SununionHoldingGroupLimitedMember 2025-09-03 0001809616 us-gaap:CommonClassBMember upc:ReorganizationMember upc:SununionHoldingGroupLimitedMember 2025-09-03 0001809616 us-gaap:CommonClassAMember upc:ReorganizationMember 2026-02-13 0001809616 upc:NasdaqCapitalMarketMember us-gaap:CommonClassAMember upc:ReorganizationMember 2026-02-13 0001809616 upc:NasdaqCapitalMarketMember us-gaap:CommonClassBMember upc:ReorganizationMember 2026-02-13 0001809616 upc:UniverseINCMember 2025-10-01 2026-03-31 0001809616 upc:UniverseTechnologyMember 2025-10-01 2026-03-31 0001809616 upc:UniverseTradeMember 2025-10-01 2026-03-31 0001809616 upc:UniverseHanheMember 2025-10-01 2026-03-31 0001809616 2024-10-01 2025-09-30 0001809616 upc:UniversePharmaceuticalsIncMember 2026-03-31 0001809616 upc:JxRcbBankMember 2025-10-01 2026-03-31 0001809616 upc:JxRcbBankMember 2026-03-31 0001809616 us-gaap:BuildingMember 2026-03-31 0001809616 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2026-03-31 0001809616 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2026-03-31 0001809616 srt:MinimumMember us-gaap:AutomobilesMember 2026-03-31 0001809616 srt:MaximumMember us-gaap:AutomobilesMember 2026-03-31 0001809616 srt:MinimumMember upc:OfficeAndElectricEquipmentMember 2026-03-31 0001809616 srt:MaximumMember upc:OfficeAndElectricEquipmentMember 2026-03-31 0001809616 us-gaap:UseRightsMember 2026-03-31 0001809616 us-gaap:TrademarksMember 2026-03-31 0001809616 us-gaap:SoftwareInDevelopmentMember 2026-03-31 0001809616 upc:RevenueFromSalesOfSelfmanufacturedTCMDProductsMember 2025-10-01 2026-03-31 0001809616 upc:RevenueFromSalesOfSelfmanufacturedTCMDProductsMember 2024-10-01 2025-03-31 0001809616 upc:RevenueFromSalesOfThirdpartyProductsMember 2025-10-01 2026-03-31 0001809616 upc:RevenueFromSalesOfThirdpartyProductsMember 2024-10-01 2025-03-31 0001809616 currency:CNY 2026-03-31 0001809616 currency:CNY 2025-03-31 0001809616 currency:CNY 2025-09-30 0001809616 currency:HKD 2026-03-31 0001809616 currency:HKD 2025-03-31 0001809616 currency:HKD 2025-09-30 0001809616 srt:ScenarioForecastMember upc:BestPraiseInternationalLimitedMember 2026-06-17 0001809616 srt:ScenarioForecastMember upc:BestPraiseInternationalLimitedMember 2026-06-17 2026-06-17 0001809616 srt:ScenarioForecastMember upc:BestPraiseInternationalLimitedMember us-gaap:CommonClassAMember 2026-06-17 2026-06-17 0001809616 upc:SharePurchaseAgreementMember 2026-03-31 0001809616 us-gaap:ConstructionInProgressMember 2026-03-31 0001809616 us-gaap:ConstructionInProgressMember 2025-09-30 0001809616 us-gaap:BuildingMember 2025-09-30 0001809616 us-gaap:MachineryAndEquipmentMember 2026-03-31 0001809616 us-gaap:MachineryAndEquipmentMember 2025-09-30 0001809616 us-gaap:AutomobilesMember 2026-03-31 0001809616 us-gaap:AutomobilesMember 2025-09-30 0001809616 us-gaap:OfficeEquipmentMember 2026-03-31 0001809616 us-gaap:OfficeEquipmentMember 2025-09-30 0001809616 upc:LandUseRightsMember 2026-03-31 0001809616 upc:LandUseRightsMember 2025-09-30 0001809616 us-gaap:TrademarksMember 2026-03-31 0001809616 us-gaap:TrademarksMember 2025-09-30 0001809616 us-gaap:SoftwareDevelopmentMember 2026-03-31 0001809616 us-gaap:SoftwareDevelopmentMember 2025-09-30 0001809616 us-gaap:ConstructionInProgressMember 2021-06-25 0001809616 upc:ChenyuanMember 2026-03-31 0001809616 2022-09-30 0001809616 us-gaap:ConstructionInProgressMember 2022-09-30 0001809616 us-gaap:ConstructionInProgressMember 2025-10-01 2026-03-31 0001809616 us-gaap:ConstructionInProgressMember 2026-03-31 2026-03-31 0001809616 upc:ConstructionInProgressTwoMember 2026-03-31 2026-03-31 0001809616 upc:JiangxiYueshangMember 2021-05-06 0001809616 2021-05-06 0001809616 2021-05-06 2021-05-06 0001809616 upc:JiangxiYueshangMember 2025-10-01 2026-03-31 0001809616 upc:UniverseTradeMember upc:LRCBankMember 2025-03-03 0001809616 upc:WorkingCapitalLoanMember upc:LRCBankMember 2025-03-03 2025-03-03 0001809616 upc:JiangxiUniverseMember upc:LRCBankMember 2025-04-22 0001809616 upc:JiangxiUniverseMember upc:LRCBankMember 2025-04-22 2025-04-22 0001809616 upc:UniverseTradeMember upc:LRCBankMember 2025-05-16 0001809616 upc:UniverseTradeMember upc:LRCBankMember 2025-05-16 2025-05-16 0001809616 upc:UniverseTradeMember upc:LRCBankMember 2026-02-28 0001809616 upc:UniverseTradeMember upc:LRCBankMember 2026-02-28 2026-02-28 0001809616 upc:JiangxiUniverseMember upc:LRCBankMember 2026-02-28 0001809616 upc:JiangxiUniverseMember upc:BankOfCommunicationsCoLtdMember 2025-09-29 0001809616 upc:JiangxiUniverseMember upc:BankOfCommunicationsCoLtdMember 2025-09-29 2025-09-29 0001809616 upc:JiangxiUniverseMember upc:ZhujiangRuralBankMember 2025-04-18 0001809616 upc:JiangxiUniverseMember upc:LRCBankMember 2025-04-18 0001809616 upc:JiangxiUniverseMember upc:LRCBankMember 2025-04-18 2025-04-18 0001809616 upc:JiangxiUniverseMember upc:BeijingBankMember 2025-09-12 0001809616 upc:JiangxiUniverseMember upc:BeijingBankMember 2025-09-12 2025-09-12 0001809616 upc:UniverseTradeMember upc:BeijingBankMember 2025-09-12 0001809616 upc:JiangxiUniverseMember upc:ZhujiangRuralBankMember 2025-06-27 0001809616 upc:JiangxiUniverseMember upc:ZhujiangRuralBankMember 2025-06-27 2025-06-27 0001809616 upc:JiangxiUniverseMember upc:HuaxiaBankMember 2025-06-27 0001809616 upc:JiangxiUniverseMember upc:PostalSavingsBankOfChinaMember 2025-07-17 0001809616 upc:JiangxiUniverseMember upc:PostalSavingsBankOfChinaMember 2025-07-17 2025-07-17 0001809616 upc:JiangxiLulingRuralCommercialBankLRCBankMember 2026-03-31 0001809616 upc:JiangxiLulingRuralCommercialBankLRCBankMember 2025-09-30 0001809616 upc:BankOfCommunicationsCoLtdMember 2026-03-31 0001809616 upc:BankOfCommunicationsCoLtdMember 2025-09-30 0001809616 upc:ZhujiangRuralBankMember 2026-03-31 0001809616 upc:ZhujiangRuralBankMember 2025-09-30 0001809616 upc:BeijingBankMember 2026-03-31 0001809616 upc:BeijingBankMember 2025-09-30 0001809616 upc:HuaxiaBankMember 2026-03-31 0001809616 upc:HuaxiaBankMember 2025-09-30 0001809616 upc:PostalSavingsBankOfChinaMember 2026-03-31 0001809616 upc:PostalSavingsBankOfChinaMember 2025-09-30 0001809616 upc:LRCBankMember 2023-11-23 0001809616 upc:LRCBankMember 2025-11-04 0001809616 upc:LRCBankMember 2026-03-31 0001809616 upc:LRCBankMember 2025-09-30 0001809616 upc:MrGangLaiMember 2024-10-01 2025-03-31 0001809616 upc:MsLinYangMember 2024-10-01 2025-03-31 0001809616 upc:MrGangLaiMember 2026-03-31 0001809616 upc:MrGangLaiMember 2025-09-30 0001809616 upc:MsLinYangMember 2026-03-31 0001809616 upc:MsLinYangMember 2025-09-30 0001809616 us-gaap:CustomerConcentrationRiskMember 2025-10-01 2026-03-31 0001809616 upc:SingleCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-10-01 2026-03-31 0001809616 upc:SingleCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-10-01 2025-03-31 0001809616 upc:TopTenCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-10-01 2026-03-31 0001809616 upc:TopTenCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-10-01 2025-03-31 0001809616 upc:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember upc:GubenYanlingPillMember 2025-10-01 2026-03-31 0001809616 upc:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember upc:GubenYanlingPillMember 2024-10-01 2025-03-31 0001809616 upc:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-10-01 2026-03-31 0001809616 upc:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-10-01 2025-03-31 0001809616 upc:PurchaseMember us-gaap:SupplierConcentrationRiskMember upc:SupplierMember 2025-10-01 2026-03-31 0001809616 upc:PurchaseMember us-gaap:SupplierConcentrationRiskMember upc:SupplierMember 2024-10-01 2025-03-31 0001809616 upc:AccountsPayableBalanceMember us-gaap:SupplierConcentrationRiskMember upc:SupplierMember 2025-10-01 2026-03-31 0001809616 upc:AccountsPayableBalanceMember us-gaap:SupplierConcentrationRiskMember upc:SupplierMember 2024-10-01 2025-03-31 0001809616 upc:UniverseINCMember us-gaap:CommonStockMember 2019-12-11 0001809616 upc:UniverseINCMember us-gaap:CommonStockMember 2020-08-07 0001809616 upc:UniverseINCMember us-gaap:CommonStockMember 2020-08-07 2020-08-07 0001809616 upc:UniverseINCMember us-gaap:CommonStockMember 2025-10-01 2026-03-31 0001809616 srt:MinimumMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-03 0001809616 srt:MinimumMember us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-03 0001809616 srt:MinimumMember us-gaap:PreferredStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-03 0001809616 srt:MaximumMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-03 0001809616 srt:MaximumMember us-gaap:PreferredStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-03 0001809616 upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-03 0001809616 upc:ShareholdersMember us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2026-03-31 0001809616 srt:MaximumMember srt:DirectorMember us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-27 0001809616 upc:ShareholdersMember srt:DirectorMember us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-27 0001809616 upc:ShareholdersMember srt:DirectorMember upc:CommonStockOneMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-27 0001809616 srt:MaximumMember srt:DirectorMember upc:CommonStockOneMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-27 0001809616 srt:MinimumMember srt:DirectorMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-27 0001809616 srt:DirectorMember us-gaap:PreferredStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-27 0001809616 srt:DirectorMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2023-07-27 0001809616 upc:ShareholdersMember srt:DirectorMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-07-15 2024-07-15 0001809616 upc:ShareholdersMember us-gaap:IPOMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-07-15 0001809616 upc:ShareholdersMember us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-07-15 0001809616 upc:ShareholdersMember us-gaap:IPOMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-07-15 2024-07-15 0001809616 upc:ShareholdersMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-07-15 2024-07-15 0001809616 upc:ShareholdersMember us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-09-27 0001809616 upc:ShareholdersMember srt:MinimumMember us-gaap:PreferredStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-09-27 0001809616 upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-09-27 0001809616 srt:BoardOfDirectorsChairmanMember us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-09-27 2024-09-27 0001809616 upc:ShareholdersMember srt:BoardOfDirectorsChairmanMember us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-09-27 0001809616 us-gaap:PreferredStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-09-27 0001809616 upc:ShareholdersMember us-gaap:PreferredStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-09-27 0001809616 upc:ShareholdersMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-11-12 0001809616 us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-11-12 0001809616 upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-11-12 0001809616 us-gaap:PreferredStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2024-11-12 0001809616 us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-03-24 0001809616 upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-03-24 0001809616 upc:ShareholdersMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-03-24 0001809616 upc:ShareholdersMember us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-03-24 0001809616 upc:CapitalReductionMember us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-09-03 0001809616 upc:CapitalReductionMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-09-03 0001809616 upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-09-03 0001809616 upc:SubDivisionMember us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-09-03 0001809616 upc:SubDivisionMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-09-03 0001809616 upc:CapitalAlterationMember us-gaap:CommonStockMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-09-03 0001809616 us-gaap:CommonClassAMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-09-03 0001809616 upc:CapitalAlterationMember us-gaap:CommonClassAMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-09-03 0001809616 us-gaap:CommonClassBMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-09-03 0001809616 upc:CapitalAlterationMember us-gaap:CommonClassBMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-09-03 0001809616 upc:NewShareClassesMember us-gaap:CommonClassBMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-09-03 0001809616 upc:NewShareClassesMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2025-09-03 2025-09-03 0001809616 upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember upc:CedeCoMember 2025-09-03 0001809616 us-gaap:CommonClassAMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember upc:CedeCoMember 2025-09-03 0001809616 upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember upc:ChristopherLinMember 2025-09-03 0001809616 us-gaap:CommonClassAMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember upc:ChristopherLinMember 2025-09-03 0001809616 upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember upc:MichaelOlsonMember 2025-09-03 0001809616 us-gaap:CommonClassAMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember upc:MichaelOlsonMember 2025-09-03 0001809616 upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember upc:DanielJSleimanMember 2025-09-03 0001809616 upc:CapitalAlterationMember us-gaap:CommonClassAMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember upc:DanielJSleimanMember 2025-09-03 0001809616 upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember upc:SununionHoldingGroupLimitedMember 2025-09-03 0001809616 us-gaap:CommonClassBMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember upc:SununionHoldingGroupLimitedMember 2025-09-03 0001809616 us-gaap:CommonClassAMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2026-02-13 0001809616 upc:NasdaqCapitalMarketMember us-gaap:CommonClassAMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2026-02-13 0001809616 upc:NasdaqCapitalMarketMember us-gaap:CommonClassBMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2026-02-13 0001809616 upc:ShareholdersMember us-gaap:CommonClassAMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2026-03-31 0001809616 upc:ShareholdersMember us-gaap:CommonClassBMember upc:IncreasedAuthorizedShareCapitalAndShareConsolidationMember 2026-03-31 0001809616 upc:UnderwriterWarrantsMember us-gaap:IPOMember 2026-03-31 0001809616 us-gaap:CommonStockMember upc:UnderwriterWarrantsMember 2026-03-31 0001809616 upc:UnderwriterWarrantsMember 2026-03-31 0001809616 upc:UnderwriterWarrantsMember upc:PurchaseAgreementMember 2024-12-06 2024-12-06 0001809616 upc:UnderwriterWarrantsMember 2024-12-06 0001809616 upc:StatutoryReserveAndRestrictedNetAssetsMember 2025-10-01 2026-03-31 0001809616 upc:JiangxiYueshangMember 2026-03-31 0001809616 upc:TwoZeroTwoSixEquityIncentivePlanMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-04-14 2026-04-14 0001809616 upc:TwoZeroTwoSixEquityIncentivePlanMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-04-14 0001809616 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2026-05-05 2026-05-05 0001809616 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember 2026-05-05 2026-05-05 0001809616 us-gaap:ParentMember 2026-03-31 0001809616 us-gaap:ParentMember 2025-09-30 0001809616 us-gaap:ParentMember us-gaap:RelatedPartyMember 2026-03-31 0001809616 us-gaap:ParentMember us-gaap:RelatedPartyMember 2025-09-30 0001809616 us-gaap:ParentMember us-gaap:CommonClassAMember 2026-03-31 0001809616 us-gaap:ParentMember us-gaap:CommonClassAMember 2025-09-30 0001809616 us-gaap:ParentMember us-gaap:CommonClassBMember 2026-03-31 0001809616 us-gaap:ParentMember us-gaap:CommonClassBMember 2025-09-30 0001809616 us-gaap:ParentMember 2025-10-01 2026-03-31 0001809616 us-gaap:ParentMember 2024-10-01 2025-03-31 0001809616 us-gaap:ParentMember 2024-09-30 0001809616 us-gaap:ParentMember 2025-03-31 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure iso4217:CNY upc:Segment utr:sqm

Exhibit 99.2

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes that appear elsewhere in the report on Form 6-K of which this document is a part. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in our annual report on Form 20-F for the fiscal year ended September 30, 2025, particularly under the caption “Item 3. Key Information—D. Risk Factors.”

Overview

Universe Pharmaceuticals INC (the “Company,” “we,” “our,” or “us”), through its PRC subsidiaries in China, is a pharmaceutical company specializing in the development, manufacturing, marketing, and sale of traditional Chinese medicine derivative (“TCMD”) products targeted to the elderly to address their physical conditions in the aging process and to promote their general well-being. We have registered and obtained approval for 26 varieties of TCMD products from the National Medical Products Administration (the “NMPA”), and we currently produce 13 varieties of TCMD products and sell them in 261 cities across 30 provinces in China as of the date of this report. In addition, we sell biomedical drugs, medical instruments, traditional Chinese medicine preparations (“TCMPs”), and dietary supplements manufactured by third-party pharmaceutical companies (collectively referred to as “third-party products”).

Our major customers are pharmaceutical companies, hospitals, clinics, and drugstore chains, primarily located in Jiangxi Province, Jiangsu Province, Guangdong Province, Hubei Province, Fujian Province, Guangxi Province, and Shandong Province, as well as 23 other provinces in China.

Key Financial Performance Indicators

In assessing our financial performance, we consider a variety of financial measures, including growth in net revenue and gross profit, as well as our ability to control costs and operating expenses in order to improve our operating efficiency and net income. Our review of these indicators facilitates timely evaluation of the performance of our business and effective communication of results and key decisions, enabling our business to respond promptly to competitive market conditions and to the evolving demands and preferences of our customers. The key measures that we use to evaluate the performance of our business are set forth below.

Net Revenue

Our revenue is reported net of all value-added taxes (“VAT”). Our products are sold with no right of return, and we do not provide credits or sales incentives to customers. Our revenue is driven by sales volume, selling price, and the mix of products sold.

		For the Six Months Ended March 31,								Variance
		2026				2025				%
Revenue from sales of self-manufactured TCMD products			64.8	%			76.2	%			(11.5	)%
Revenue from sales of third-party products			35.2	%			23.8	%			11.5	%
Total revenue			100.0	%			100.0	%
Sales volume by unit- TCMD products			4,462,825				6,050,384				(26.2	)%
Sales volume by unit- third party products			2,162,920				2,676,396				(19.2	)%
Total sales volume			6,625,745				8,726,780				(24.1	)%
Average selling price per unit- TCMD products		$	1.31			$	1.15				13.9	%
Average selling price per unit- Third-party products		$	1.47			$	0.81				81.5	%

Revenues from sales of TCMD products manufactured by us accounted for 64.8% and 76.2% of our total revenues for the six months ended March 31, 2026 and 2025, respectively. The 13 TCMD products manufactured by us fall into two categories: (i) treatments and relief for common chronic health conditions in the elderly, designed to achieve physical wellness and longevity (the “Chronic Condition Treatments”), and (ii) cold and flu medications. Our Chronic Condition Treatments primarily include Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor, and our cold and flu medications primarily include Paracetamol Granule for Children, Isatis Root Granule, and Qiangli Pipa Syrup.

In order to diversify our product offerings and product mix, in addition to selling our self-manufactured TCMD products, we also sell products manufactured by third-party pharmaceutical companies, including (i) biomedical drugs, such as liquid glucose, prednisolone, and citicoline, (ii) medical instruments, such as drug-eluting stents, surgical tubes, and syringes, (iii) TCMPs, such as red sage tablets, Longdan Xiegan pills, and Chinese skullcap capsules, and (iv) dietary supplements, such as vitamins, probiotic powder, and calcium tablets. Revenues from sales of third-party products accounted for 35.2% and 23.8% of our total revenues for the six months ended March 31, 2026 and 2025, respectively.

Gross Profit

Gross profit is equal to net revenue minus cost of goods sold. Cost of goods sold primarily includes inventory costs (raw materials, labor, packaging costs, depreciation and amortization, third-party product purchase price, freight costs, and overhead). Cost of goods sold generally changes in line with our production costs, which are affected by factors including the market price of raw materials, labor productivity, and the purchase price of third-party products, as well as changes in customer and product mix. Our cost of revenues accounted for 63.0% and 65.4% of our total revenue for the six months ended March 31, 2026 and 2025, respectively. We expect our cost of revenues to increase as we further expand our operations in the foreseeable future.

Our gross margin was 37.0% for the six months ended March 31, 2026, an increase of 2.4 percentage points from the gross margin of 34.6% for the six months ended March 31, 2025, due to increases in the average selling price of our TCMD products and third-party products of 13.9% and 81.5%, respectively.

Operating Expenses

Our operating expenses consist of selling expenses, general and administrative expenses and research and development expenses.

Our selling expenses primarily include salary and welfare benefit expenses paid to our sales personnel, advertising expenses to increase the awareness of our brand, shipping and delivery expenses, and expenses incurred for business travel, meals, and other sales promotion and marketing activities. Our selling expenses accounted for 36.4% and 24.9% of our total revenue for the six months ended March 31, 2026 and 2025, respectively. We expect our overall selling expenses, including, but not limited to, advertising expenses, brand promotion expenses, and salaries, to increase in the foreseeable future as we continue to expand our business and promote our products to customers across expanded geographic areas.

Our general and administrative expenses primarily consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and maintenance expenses, office supply and utility expenses, business travel and meals expenses, land and property taxes and professional service expenses. General and administrative expenses accounted for 16.2% and 34.1% of our revenue for the six months ended March 31, 2026 and 2025, respectively. We expect our general and administrative expenses, including, but not limited to, salaries and business consulting expenses, to increase in the foreseeable future, as we plan to hire additional personnel and incur additional expenses in connection with the expansion of our business operations.

2

The Chinese patent medicine industry is characterized by rapid and frequent changes in customer demand and the launch of new products. If we do not launch new products or improve our existing products to meet the changing demands of our customers in a timely manner, some of our products could become uncompetitive in the market, thereby adversely affecting our revenues and operating results. Our research and development expenses primarily consist of salaries, welfare and insurance expenses paid to our employees involved in research and development activities, materials and supplies used in the development and testing of new TCMD products, depreciation, and other miscellaneous expenses. Research and development expenses accounted for 1.0% and 1.1% of our revenue for the six months ended March 31, 2026 and 2025, respectively. As we continue to develop new products and diversify our product offerings to satisfy customer demand, we expect our research and development expenses to increase in the foreseeable future.

Financial Results for the Six Months Ended March 31, 2026 Compared to the Six Months Ended March 31, 2025

The following table summarizes the results of our operations for the six months ended March 31, 2026 and 2025, respectively, and provides information regarding the dollar and percentage increase or (decrease) during such periods.

		For the Six Months Ended March 31,
		2026								2025								Variance
		Amount				% of revenue				Amount				% of revenue				Amount				%
REVENUE		$	9,036,190				100.0	%		$	9,152,915				100.0	%		$	(116,725	)			(1.3	)%
COST OF REVENUE			5,693,679				63.0	%			5,988,385				65.4	%			(294,706	)			(4.9	)%
GROSS PROFIT			3,342,511				37.0	%			3,164,530				34.6	%			177,981				5.6	%
OPERATING EXPENSES
Selling expenses			3,285,367				36.4	%			2,276,728				24.9	%			1,008,639				44.3	%
General and administrative expenses			1,463,798				16.2	%			3,117,727				34.1	%			(1,653,929	)			(53.0	)%
Research and development expenses			93,478				1.0	%			96,836				1.1	%			(3,358	)			(3.5	)%
Total operating expenses			4,842,643				53.6	%			5,491,291				60.0	%			(648,648	)			(11.8	)%
LOSS FROM OPERATIONS			(1,500,132	)			(16.6	)%			(2,326,761	)			(25.4	)%			826,629				(35.5	)%
OTHER INCOME (EXPENSE)
Interest expense, net			(126,157	)			(1.4	)%			(128,745	)			(1.4	)%			2,588				(2.0	)%
Other income, net			71,476				0.8	%			(829,249	)			(9.1	)%			900,725				(108.6	)%
Total other loss, net			(54,681	)			(0.6	)%			(957,994	)			(10.5	)%			903,313				(94.3	)%
INCOME TAX			(1,554,813	)			(17.2	)%			(3,284,755	)			(35.9	)%			1,729,942				(52.7	)%
PROVISION FOR INCOME TAXES			-				-	%			-				-	%			-				-	%
NET LOSS		$	(1,554,813	)			(17.2	)%		$	(3,284,755	)			(35.9	)%			1,729,942				(52.7	)%

Revenues. We currently produce and sell 13 varieties of TCMD products and also sell products manufactured by third-party pharmaceutical companies, to our customers.

		For the Six Months Ended March 31,
		2026				2025				Change
		Amount				Amount				Amount				%
Revenue - TCMD products sales		$	5,850,980			$	6,978,932			$	(1,127,952	)			(16.2	)%
Revenue – third-party products sales			3,185,210				2,173,983				1,011,227				46.5	%
Total revenue		$	9,036,190			$	9,152,915			$	(116,725	)			(1.3	)%

Our revenues decreased by $116,725, or 1.3%, to $9,036,190 for the six months ended March 31, 2026, from $9,152,915 for the six months ended March 31, 2025.

3

Revenue from sales of our TCMD products

Sales of TCMD products decreased by $1,127,952, or 16.2%, to $5,850,980 for the six months ended March 31, 2026, from $6,978,932 for the six months ended March 31, 2025. The decrease in sales of our TCMD products was attributable to the following reasons:

a) The nationwide centralized drug procurement policy implemented in China led to a significant decrease in the prices of certain essential medicines and intensified competitive differentiation within the industry, making it increasingly difficult for small and medium-sized enterprises to compete with leading enterprises. As a result, our sales volume of TCMD products decreased by 1,587,559 units, or 26.2%, to 4,462,825 units sold in the six months ended March 31, 2026, from 6,050,384 units sold in the six months ended March 31, 2025.

b) The average selling price of our TCMD products increased by $0.16 per unit, or 13.9%, to $1.31 per unit in the six months ended March 31, 2026, from $1.15 per unit in the six months ended March 31, 2025, due to a change in product mix.

c) The exchange rate between RMB and US$ was US$1.00 to RMB7.2308 in the six months ended March 31, 2025 as compared to US$1.00 to RMB7.0061 in the six months ended March 31, 2026. The appreciation of RMB against US$ had a 3.1% positive impact on our reported revenues.

Revenue from sales of third-party products

Sales of third-party products increased by $1,011,227, or 46.5%, to $3,185,210 for the six months ended March 31, 2026, from $2,173,983 for the six months ended March 31, 2025. Sales volume of third-party products decreased by 19.2%, to 2,162,920 units sold in the six months ended March 31, 2026, from 2,676,396 units sold in the six months ended March 31, 2025. The average selling price of third-party products increased by $0.66 per unit, or 81.5%, to $1.47 per unit in the six months ended March 31, 2026, from $0.81 per unit in the six months ended March 31, 2025, attributable to our new sales strategy of focusing on the promotion of Traditional Chinese Medicine Pieces with higher average selling prices and gross profit margins in order to improve our overall profitability.

Cost of Revenues. Our cost of revenues primarily consists of inventory costs (including raw materials, labor, packaging costs, depreciation and amortization, third-party product purchase prices, freight costs, and overhead) and business tax. Cost of revenues generally changes as our production costs change, which are affected by factors such as the market price of raw materials, labor productivity, and the purchase price of third-party products, as well as changes in customer and product mix.

		For the Six Months Ended March 31,
		2026				2025				Change
		Amount				Amount				Amount				%
Cost of revenue- TCMD products		$	3,773,396			$	4,640,381			$	(866,985	)			(18.7	)%
Cost of revenue- third-party products			1,920,283				1,348,004				572,279				42.5	%
Total cost of revenue		$	5,693,679			$	5,988,385			$	(294,706	)			(4.9	)%

Cost of revenues decreased by $294,706, or 4.9%, to $5,693,679 for the six months ended March 31, 2026, from $5,988,385 for the six months ended March 31, 2025, due to a decrease in sales volume.

4

Cost of revenues of TCMD products

Cost of revenues of TCMD products accounted for 66.3% and 77.5% of our total cost of revenues for the six months ended March 31, 2026 and 2025, respectively. Cost of revenues of TCMD products decreased by $866,985, or 18.7%, from $4,640,381 in the six months ended March 31, 2025 to $3,773,396 in the six months ended March 31, 2026. The decrease in cost of revenues of our TCMD products was due to the following reasons:

(1) Sales volume of our TCMD products decreased by 26.2%, to 4,462,825 units sold in the six months ended March 31, 2026, from 6,050,384 units sold in the six months ended March 31, 2025.

(2) The average per unit cost of our TCMD products increased by $0.08, or 10.4%, from $0.77 per unit in the six months ended March 31, 2025 to $0.85 per unit in the six months ended March 31, 2026, due to a change in product mix.

(3) The 3.1% positive impact from foreign currency fluctuation as discussed above.

Cost of revenues of third-party products

Cost of revenues of third-party products accounted for 33.7% and 22.5% of our total cost of revenues for the six months ended March 31, 2026 and 2025, respectively. Cost of revenues of third-party products increased by $572,279, or 42.5%, from $1,348,004 in the six months ended March 31, 2025 to $1,920,283 in the six months ended March 31, 2026. The increase was primarily attributable to an increase in the average per unit cost of third-party products by $0.39 per unit, or 78.0%, from $0.50 per unit in the six months ended March 31, 2025 to $0.89 per unit in the six months ended March 31, 2026, consistent with the increase in average selling price as a result of our new sales strategy as discussed above. Sales volume of our third-party products decreased by 19.2%, from 2,676,396 units sold in the six months ended March 31, 2025 to 2,162,920 units sold in the six months ended March 31, 2026.

Gross profit

Our gross profit increased by $177,981, or 5.6%, to $3,342,511 for the six months ended March 31, 2026, from $3,164,530 for the six months ended March 31, 2025. Our gross margin increased by 2.4 percentage points to 37.0% for the six months ended March 31, 2026, from 34.6% for the six months ended March 31, 2025.

		For the Six Months Ended March 31,
		2026				2025				Change
		Amount				Amount				Amount				%
Gross profit- TCMD products		$	2,077,584			$	2,338,551			$	(260,967	)			(11.2	)%
Gross profit- third-party products			1,264,927				825,979				438,948				53.1	%
Total gross profit		$	3,342,511			$	3,164,530			$	177,981				5.6	%
Gross margin- TCMD products			35.5	%			33.5	%							2.0	%
Gross margin- third party products			39.7	%			38.0	%							1.7	%
Total gross margin			37.0	%			34.6	%							2.4	%
Average selling price per unit- TCMD products		$	1.31			$	1.15			$	0.16				13.9	%
Average cost per unit- TCMD products		$	0.85			$	0.77			$	0.08				10.4	%
Average selling price per unit- third party products		$	1.47			$	0.81			$	0.66				81.5	%
Average cost per unit - third party products		$	0.89			$	0.50			$	0.39				78.0	%

Gross profit from the sales of our TCMD products decreased by $260,967, or 11.2%, from $2,338,551 in the six months ended March 31, 2025 to $2,077,584 in the six months ended March 31, 2026, and the gross margin of our TCMD products increased by 2.0 percentage points, from 33.5% in the six months ended March 31, 2025 to 35.5% in the six months ended March 31, 2026. The decrease in our gross profit from the sales of TCMD products was primarily attributable to the decrease in sales volume.

5

Gross profit from third-party product sales increased by $438,948, or 53.1%, from $825,979 in the six months ended March 31, 2025 to $1,264,927 in the six months ended March 31, 2026, while the gross margin of third-party product sales increased by 1.7 percentage points, from 38.0% in the six months ended March 31, 2025 to 39.7% in the six months ended March 31, 2026. The increase in our gross profit from third-party products was primarily driven by the increase in average unit selling price, partially offset by the decrease in sales volume and the increase in average per unit cost.

Operating expenses

The following table sets forth the breakdown of our operating expenses for the six months ended March 31, 2026 and 2025:

		For the Six Months Ended March 31,
		2026								2025								Variance
		Amount				% of revenue				Amount				% of revenue				Amount				%
Total revenue		$	9,036,190				100.0	%		$	9,152,915				100.0	%		$	(116,725	)			(1.3	)%
Operating expenses:
Selling expenses			3,285,367				36.4	%			2,276,728				24.9	%			1,008,639				44.3	%
General and administrative expenses			1,463,798				16.2	%			3,117,727				34.1	%			(1,653,929	)			(53.0	)%
Research and development expenses			93,478				1.0	%			96,836				1.1	%			(3,358	)			(3.5	)%
Total operating expenses		$	4,842,643				53.6	%		$	5,491,291				60.0	%		$	(648,648	)			(11.8	)%

Selling expenses

Our selling expenses primarily consist of salaries and employee benefit expenses paid to our sales personnel, advertising expenses to increase our brand awareness, shipping and delivery expenses, business travel and meals expenses, and other sales promotion and marketing activities-related expenses.

		For the Six Months Ended March 31,
		2026								2025								Variance
		Amount				%				Amount				%				Amount				%
Salary and employee benefit expenses		$	542,177				16.5	%		$	481,136				21.1	%		$	61,041				12.7	%
Advertising expenses			1,912,566				58.2	%			1,248,783				54.8	%			663,783				53.2	%
Shipping and delivery expenses			476,681				14.5	%			389,133				17.1	%			87,548				22.5	%
Business travel and meals expenses			169,745				5.2	%			140,066				6.2	%			29,679				21.2	%
Market research expenses			170,709				5.2	%			-				-	%			170,709				-	%
Other sales promotion related expenses			13,489				0.4	%			17,610				0.8	%			(4,121	)			(23.4	)%
Total selling expenses		$	3,285,367				100.0	%		$	2,276,728				100.0	%		$	1,008,639				44.3	%

Selling expenses increased by $1,008,639, or 44.3%, to $3,285,367 for the six months ended March 31, 2026, from $2,276,728 for the six months ended March 31, 2025, primarily attributable to increases in advertising expenses and market research expenses of $663,783 and $170,709, respectively. The Company renewed its advertising service agreement with Health Headline to promote its brand on Health Headline’s website and mobile application, which contributed to a significant increase in advertising expenses and market research expenses during the six months ended March 31, 2026.

6

General and Administrative Expenses

Our general and administrative expenses primarily consist of employee salaries, welfare and insurance expenses, depreciation, bad debt provisions, inspection and maintenance expenses, office supply and utility expenses, business travel and meals expenses, land and property taxes, and professional service expenses.

		For the Six Months Ended March 31,
		2026								2025								Variance
		Amount				%				Amount				%				Amount				%
Salary and employee benefit expenses		$	424,745				29.0	%		$	454,706				14.6	%		$	(29,961	)			(6.6	)%
Depreciation and amortization			109,265				7.5	%			124,596				4.0	%			(15,331	)			(12.3	)%
Office supply and utility expense			121,350				8.3	%			58,984				1.9	%			62,366				105.7	%
Transportation, business travel and meals expense			77,594				5.3	%			114,168				3.7	%			(36,574	)			(32.0	)%
Consulting fee			715,449				48.9	%			2,300,041				73.8	%			(1,584,592	)			(68.9	)%
Inspection and maintenance fee			7,225				0.5	%			10,871				0.3	%			(3,646	)			(33.5	)%
Stamp tax and other expenses			8,170				0.6	%			54,361				1.7	%			(46,191	)			(85.0	)%
Total general and administrative expenses		$	1,463,798				100.0	%		$	3,117,727				100.0	%		$	(1,653,929	)			(53.0	)%

General and administrative expenses decreased by $1,653,929, or 53.0%, to $1,463,798 for the six months ended March 31, 2026, from $3,117,727 for the six months ended March 31, 2025, primarily attributable to a decrease in consulting fees of $1,584,592. The Company incurred underwriting expenses and legal fees of $1,394,453 in connection with the Company’s registered direct offering closed on December 6, 2024. No such expenses were incurred during the six months ended March 31, 2026.

Research and development expenses

Our research and development expenses primarily consist of salaries, welfare and insurance expenses paid to our employees involved in research and development activities, materials and supplies used in the development and testing of new TCMD products, depreciation and other miscellaneous expenses.

		For the Six Months Ended March 31,
		2026								2025								Variance
		Amount				%				Amount				%				Amount				%
Salary and employee benefit expenses for research and development personnel		$	53,069				56.8	%		$	55,327				57.1	%		$	(2,258	)			(4.1	)%
Materials used in research and development activities			1,240				1.3	%			-				0.0	%			1,240				-	%
Expenditure on new product development			32,134				34.4	%			31,603				32.6	%			531				1.7	%
Depreciation and others			7,035				7.5	%			9,906				10.2	%			(2,871	)			(29.0	)%
Total research and development expenses		$	93,478				100.0	%		$	96,836				100.0	%		$	(3,358	)			(3.5	)%

Research and development expenses decreased by $3,358, or 3.5%, to $93,478 for the six months ended March 31, 2026, from $96,836 for the six months ended March 31, 2025, primarily attributable to a decrease in depreciation and other expenses of $2,871 as a portion of our production equipment reached the end of its expected useful life.

Other income (expenses), net

Total other expenses, net was $54,681 for the six months ended March 31, 2026, compared to $957,994 for the six months ended March 31, 2025. Exchange loss was $84,258 for the six months ended March 31, 2026, representing a decrease of $871,404 from the exchange loss of $955,662 recorded for the six months ended March 31, 2025.

Provision for Income Taxes

Income tax expense was nil for the six months ended March 31, 2026 and 2025.

7

Net Loss

Net loss was $1,554,813 for the six months ended March 31, 2026, compared to a net loss of $3,284,755 for the six months ended March 31, 2025.

Basic and diluted loss per share were $2.76 for the six months ended March 31, 2026, compared to $9.44 for the six months ended March 31, 2025. The weighted average number of shares outstanding increased from 347,814 for the six months ended March 31, 2025 to 563,338 for the six months ended March 31, 2026, primarily due to the issuance of 18,750,000 shares (equivalent to 468,750 shares after giving effect to the 40-for-1 share consolidation effected on March 24, 2025) in connection with a Securities Purchase Agreement entered into on December 6, 2024.

Liquidity and Capital Resources

As of March 31, 2026, we had $27.6 million in cash on hand. We also had short-term investments of $1.5 million in wealth management financial products from financial institutions to generate investment income, which we purchased with proceeds from the issuance of ordinary shares. Such short-term investments can be redeemed at any time at our discretion and are highly liquid. As of March 31, 2026, we also had $15.0 million in accounts receivable. Our accounts receivable primarily include balances due from customers for our pharmaceutical products sold and delivered to customers. Approximately 38.0%, or $5.7 million, of our net accounts receivable balance as of March 31, 2026 have been subsequently collected. Collected accounts receivable will be used as working capital in our operations, if necessary.

As of March 31, 2026, our inventory balance amounted to $2.0 million, primarily consisting of raw materials, work-in-progress and finished TCMD products, which we believe can be sold quickly based on our analysis of current demand trends for our products.

On June 25, 2021, we entered into a construction agreement with a sub-contractor, Jiangxi Chenyuan Construction Project Co., Ltd. (“Chenyuan”), for the construction of four manufacturing plant buildings and an office building with a total estimated budget of RMB165 million (approximately $23.9 million). As of March 31, 2026, we had made a prepayment of approximately RMB69.2 million (approximately $10.0 million) to Chenyuan and future additional capital expenditure on this construction-in-process (“CIP”) project is estimated to be approximately RMB95.8 million (equivalent to $13.9 million), among which approximately $3.6 million is required for the next 12 months. In April 2025, the Ministry of Emergency Management of the PRC issued the Specification for Safety Management of Fine Chemical Enterprises, pursuant to which enterprises are prohibited from setting up employee dormitories within factory premises. The Company was required to redesign the project, and the expected completion date has been further delayed to June 30, 2028. We currently plan to support our ongoing CIP project through cash collected from accounts receivable, and if necessary, borrowings from banks.

On May 6, 2021, we entered into a real estate property purchase agreement with Jiangxi Yueshang to purchase certain residential apartments and commercial office space totaling 2,749.30 square meters, with a total purchase price of RMB32 million (approximately $4.6 million). As of March 31, 2026, we had made a prepayment of RMB16 million (approximately $2.3 million) to Jiangxi Yueshang. The remaining balance of RMB16 million (approximately $2.3 million) is expected to be paid upon receipt of the Real Estate Ownership Certificate.

As of March 31, 2026, we also had short-term bank loans of $7.4 million and long-term bank loans of $2.2 million that we obtained from several PRC banks for working capital purposes. We expect that we will be able to renew all of the existing bank loans upon their maturity based on our past experiences and our outstanding credit history.

As of March 31, 2026, our working capital balance was $41.6 million. In assessing our liquidity, management monitors and analyzes our cash on-hand, our ability to generate sufficient revenue in the future, and our operating and capital expenditure commitments. We believe that our current cash and cash flows provided by operating activities, borrowings from banks and from our principal shareholders will be sufficient to meet our working capital needs in the next 12 months from the date of this report.

8

The following table sets forth a summary of our cash flows for the periods indicated:

		For the Six Months Ended March 31,
		2026				2025
Net cash (used in) provided by operating activities		$	(4,298,208	)		$	2,561,194
Net cash used in investing activities			(1,812,650	)			(132,737	)
Net cash (used in) provided by financing activities			(149,072	)			16,398,355
Effect of exchange rate change on cash and restricted cash			227,635				(1,051,654	)
Net (decrease) increase in cash			(6,032,295	)			17,775,158
Cash, beginning of period			33,592,025				29,497,693
Cash, end of period		$	27,559,730			$	47,272,851

Operating Activities

Net cash used in operating activities was $4,298,208 for the six months ended March 31, 2026, and consisted primarily of the following:

● Net loss of $1,554,813 for the period.

● An increase in other receivable of $4,794,563. On June 17, 2026, we entered into a Share Purchase Agreement (the “SPA”) with Ms. Lu Shanshan (“Ms. Lu”), pursuant to which we agreed to acquire 100% of the issued shares (the “Target Shares”) of Best Praise International Limited (the “Target”) for a consideration of US$10,751,000, payable entirely through the issuance of 4,376,552 of our Class A ordinary shares (the “Consideration Shares”) to Ms. Lu or her designated recipients, subject to the terms and conditions set forth in the SPA. The Company prepaid $5,223,594 as a security deposit for the SPA as of March 31, 2026.

● An increase in accounts payable of $1,999,735 due to pending invoices from suppliers for raw materials purchased in the first quarter of 2026.

● An increase in accounts receivable of $1,507,555. We provided longer credit terms for our regular customers to maintain customer relationships and promote sales.

Net cash provided by operating activities was $2,561,194 for the six months ended March 31, 2025, primarily consisting of the following:

● Net loss of $3,284,755 for the period.

● A decrease in other receivable of $3,555,781. On September 26, 2022, the Company entered into a letter of intent for an equity transfer with an individual, Mr. Xibo Liu, pursuant to which Mr. Xibo Liu agreed to transfer his 51% ownership in Yunnan Faxi to the Company at a price of RMB72 million (approximately $10.0 million). Based on the contract terms, the Company prepaid RMB25 million (approximately $3.4 million) within three (3) business days of signing the letter of intent. However, due to the unsatisfactory performance of Yunnan Faxi, the equity transfer contract was terminated on December 20, 2024. The amount of $3,562,472 (RMB25 million) was recorded as other receivable as of September 30, 2024 and was collected during the six months ended March 31, 2025.

● An increase in accounts payable of $2,657,313 due to pending invoices from suppliers for raw materials purchased in the first quarter of 2025.

● A decrease in accounts receivable of $2,318,451. Our accounts receivable primarily include balance due from customers for our pharmaceutical products sold and delivered to customers. We enhanced our accounts receivable management and shortened the accounts receivable collection period during the six months ended March 31, 2025.

9

● An increase in inventory balance of $1,892,889 because we increased inventory stockpiles to reduce the negative impact from the increase in market prices of Chinese traditional medicine raw materials.

● An increase in advance to suppliers of $1,057,671 to ensure continuous high-quality supplies and favorable purchase prices of raw materials.

Investing Activities

Net cash used in investing activities amounted to $1,812,650 for the six months ended March 31, 2026, due to purchase of short-term investments of $1,490,203, purchase of fixed assets of $311,028, and purchase of intangible assets of $11,419.

Net cash used in investing activities amounted to $132,737 for the six months ended March 31, 2025, due to purchase of fixed assets of $84,333, purchase of intangible assets of $35,957, and prepayments for construction in progress of $12,447.

Financing Activities

Net cash used in financing activities amounted to $149,072 for the six months ended March 31, 2026, primarily consisted of the following:

● Proceeds from bank loans of $3,568,319 and repayment of bank loans of $3,568,319.

● Repayment of related party borrowings of $149,072. The balance due to a related party mainly consisted of advances from Mr. Gang Lai for working capital purposes during our normal course of business. These advances were non-interest bearing and due on demand.

Net cash provided by financing activities amounted to $16,398,355 for the six months ended March 31, 2025, primarily consisted of the following:

● Net proceeds from issuance of ordinary shares of $15,000,000.

● Proceeds from bank loans of $691,486 and repayment of bank loans of $691,486.

● Proceeds from related party borrowings of $1,398,355. The balance due to related party mainly consisted of advances from Mr. Gang Lai for working capital purposes during our normal course of business. These advances were non-interest bearing and due on demand.

Commitments and contingencies

From time to time, we may be a party to various legal actions arising in the ordinary course of business. We accrue costs associated with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. For the six months ended March 31, 2026 and 2025, we did not have any legal claims or litigation pending.

As of March 31, 2026, we had the following contractual obligations:

			Payments Due by Period
Contractual Obligations			Total				Less than 1 year				1-2 years				2-3 years				3-4 years
(1)	Debt Obligations		$	9,553,493			$	7,378,950			$	-			$	2,174,543			$	-
(2)	Capital expenditure commitment on CIP project			13,888,084				3,624,239				3,624,239				5,443,607				1,195,999
(3)	Capital expenditure commitment for purchase of property			2,319,513				2,319,513				-				-				-
Total			$	25,761,090			$	13,322,702			$	3,624,239			$	7,618,150			$	1,195,999

10

(1) As of March 31, 2026, we had a total of $7,378,950 in short-term borrowings and $2,174,543 in long-term borrowings from several PRC banks (see Footnotes 12 and 13 of our unaudited consolidated financial statements and footnotes, for details).

(2) On June 25, 2021, we signed a construction sub-contract with Chenyuan, pursuant to which, Chenyuan will help us construct four manufacturing plant buildings and an office building with a total estimated budget of RMB165 million (approximately $23.9 million). As of March 31, 2026, we had made a prepayment of approximately RMB69.2 million (approximately $10.0 million) to Chenyuan and future additional capital expenditure on this CIP project was estimated to be approximately RMB95.8 million (approximately $13.9 million) (see Footnote 10 of our unaudited condensed consolidated financial statements and footnotes, Prepayment for CIP project, for details).

(3) On May 6, 2021, we entered into a real estate property purchase agreement with Jiangxi Yueshang to purchase certain residential apartments and commercial office space totaling 2,749.30 square meters, with a total purchase price of RMB32 million (approximately $4.6 million). As of March 31, 2026, we had made a prepayment of RMB16 million (approximately $2.3 million) to Jiangxi Yueshang. The remaining balance of RMB16 million (approximately $2.3 million) is expected to be paid upon reception of the Real Estate Ownership Certificate (see Footnote 11 of our unaudited condensed consolidated financial statements and footnotes, Prepayment for purchase of a property, for details).

Trend Information

Other than as disclosed elsewhere in this report, we are not aware of any trends, uncertainties, demands, commitments, or events that are reasonably likely to have a material effect on our net revenues, income from continuing operations, profitability, liquidity, or capital resources, or that would cause reported financial information not necessarily to be indicative of future operating results or financial condition.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements as of either March 31, 2026 or September 30, 2025.

Inflation

Inflation does not materially affect our business or the results of our operations.

Seasonality

Seasonality does not materially affect our business or the results of our operations.

11

Filing Exhibits & Attachments

7 documents

Press Releases

• EX-99.1 UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS AND RELATED NOTES AS OF MARCH 31, 20 771.9 KB
• EX-99.2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA 203.1 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 71.3 KB
• EX-101 XBRL CALCULATION FILE 62.4 KB
• EX-101 XBRL DEFINITION FILE 373.9 KB
• EX-101 XBRL LABEL FILE 563.9 KB
• EX-101 XBRL PRESENTATION FILE 393.7 KB